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Preface
This is the fourth publication in the EMCDDA’s Manuals series, and after those on the evaluation 
of drug demand reduction practices, it is the first to address issues related to the illicit drug market. 
Prices are an essential element of the drug market, from both a demand and a supply perspective. 
Drug prices, together with information on drug purity, may be used as indicators of drug 
availability, and as contextual information for the epidemiology of drug use. There is in general 
an assumed relationship between retail drug prices and drug use, as prices may influence the 
level and incidence of drug consumption, either directly or via the mediation of other factors. 
Drug prices, combined with other market indicators, are also an important tool for understanding 
the workings of drug supply and distribution mechanisms; they are fundamental to estimating the 
value of drug markets and their potential impact on the legal economy. They may, in particular, be 
used to help target law enforcement resources and review supply reduction strategies. Lastly, drug 
prices are also used in many countries by criminal justice agencies to assist with decisions related 
to prosecution and sentencing, for example in cases of assets recovery.
The EMCDDA has been collecting information on retail prices via its Reitox network of national 
focal points for the last 15 years. Although considerable progress has been achieved and 
aggregated annual data are now made available from all reporting countries, there is still 
substantial variation in terms of the methods of data collection both between and within countries. 
This raises concerns over the reliability and comparability of data on retail prices across Europe. 
This Manual builds on initial discussions held at an expert meeting organised by the EMCDDA in 
October 2007, which examined differences in national reporting practices of retail drug prices 
data in Europe. Disseminating information on issues relating to the recording of retail drug prices 
was identified as a method of helping local and national information providers improve their data 
collection strategies.
The main objective of the Manual is to raise awareness on a series of key issues related to 
collecting data on retail drug prices and provide useful general suggestions. The target readership 
comprises all those involved in the data collection of drug prices, specifically at the retail level, in 
Europe.
The first issue the Manual addresses is the difficulty in obtaining an operational definition of 
‘retail’ prices. The next difficulty discussed relates to sampling and the challenge of obtaining 
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a representative sample of illicit, and therefore hidden, transactions. The factors that can affect 
drug prices, e.g. drug quality, transaction size, setting and buyer’s experience, are outlined and 
suggestions made for a minimum set of variables to be recorded for each observation.
The guidelines provide a review of the main methods of data collection in Europe. This 
encompasses both the tactics set up by law enforcement agencies with price data being provided 
via the use of covert purchases, confidential informants, or even arrestees; and research methods 
that may allow price data to be obtained via overt purchases, key experts, or directly from users. 
Whenever possible, examples from current national practices are provided.
The Manual also addresses some practical issues relating to data collection, management and 
analysis. In particular, it discusses the need for defining cut-off points as a way to select only those 
transactions that are deemed to be retail. Some basic advice is provided for data recording, data 
cleaning, construction of the matrix and validation procedures. Standard descriptive measures are 
suggested, and feedback to data providers and publication of the results is encouraged.  
Although reference is made to ‘best practice’ throughout the text, it does not comprise an 
exhaustive study, or a strict prescription to be applied in every context; particularly in relation 
to technical issues such as sampling, consideration of the specific circumstances of the data 
collection and reference to the literature is required.
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Chapter 1
Introduction
Following a brief introductory discussion of the different uses of drug price data, this chapter 
reviews the activities carried out by international organisations to collect such data, the data 
collection methods used in Europe and beyond, and the objectives of the present document.
Why collect data on (retail) drug prices?
Retail drug prices are an important element in assessing the availability of illicit drugs at user level, 
and have been often used together with data on purity and potency as contextual information for 
the epidemiology of drug use.
First, there is in general an assumed relationship between drug use and retail drug prices, as 
prices may influence current drug consumption and incidence (new persons starting to use drugs). 
However, the nature of this relationship is not universal, and may depend on a range of factors 
such as price levels, income, the availability of alternative products, the type of drug consumed, 
and the stage of the user’s drug career.
There is a considerable volume of research analysing the link between drug use and prices but it 
focuses mainly on licit drugs such as alcohol and tobacco (e.g. Cook et al., 2005; Chaloupka and 
Wechsler, 1995). There is also some evidence that illicit drug users’ reactions to increases in retail 
drug prices are consistent with evidence from demand for licit addictive substances. Studies show 
that changes in illicit drug use are inversely related to changes in retail prices, both in the short 
and the long run (Nisbet and Vakil, 1972; Saffer and Chaloupka, 1995; Rhodes et al., 2002; 
Caulkins, 1995b; Chaloupka and Pacula, 2000; Bretteville-Jensen and Biørn, 2003, 2004;  
Dave, 2008).
As has also been shown for tobacco (Chaloupka et al., 2000), drug users’ reactions to drug price 
changes may depend on the price level itself — i.e. increases in a fairly low price may not have 
any significant impact on current use; or slight decreases in prices that are already quite high may 
not lead to a corresponding increase in the number of new users.
Drug users’ available income also has an impact on the extent and patterns of drug use, i.e. 
sensitivity to changes in retail drug price may depend on the share of individual disposable 
income that is spent for buying illicit drugs or tobacco. The greater the share, the greater  
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the sensitivity to price increases. Similarly, the price of each drug in relation to the price of 
substances that the user considers to be alternative products (e.g. alcohol) will affect drug use 
(Bretteville-Jensen, 2006).
The type of drug may also influence the relationship between drug prices and drug use, different 
psychoactive substances leading to different addiction patterns and therefore to different 
responses to price changes. It is interesting to note that prices may also influence the route of 
administration of the drug — users in Norway have claimed, for example, that cheaper heroin 
would make smoking a more attractive alternative since they would need three times as much 
heroin to get the same ‘high’ if they smoked the drug instead of injecting it (Bretteville-Jensen, 
personal communication).
In addition, empirical evidence points to different behaviours in relation to prices depending on 
the stage of the user’s drug career. It has been shown that in the initiation phase, when they are 
not yet dependent, drug users may be more sensitive to drug prices than in later stages when they 
are using regularly and are addicted to the drug (Bretteville-Jensen, 2006). New users may be 
particularly influenced by drug prices (Caulkins and Reuter, 1996), in that they may be attracted 
to use certain products because they are relatively affordable, while high prices may have a 
deterrent effect on potential new entries into the drug using population. While the arguments why 
non-dependent users are price responsive are persuasive, dependent users typically spend a 
large share of their disposable income on drugs, suggesting that they may also be influenced by 
price. But while the arguments why non-dependent users would be more price responsive sound 
persuasive, there are strong arguments why dependent users would be more price responsive than 
non-dependent users (dependent users typically spend a greater share of their disposable income 
on the drug).
Studies have shown that dependent drug users may commit income-generating crimes  
(e.g. property crimes, drug dealing) as a means of supporting their drug habits, and therefore 
although the relationship between drug use and crime is neither simple nor universal (EMCDDA, 
2007), it is likely that, faced with drug price increases, some users might increase their 
involvement in criminal activities while others would rather reduce their consumption by seeking 
treatment (MacCoun et al., 2003).
Second, drug prices are an important tool for understanding the workings of drug distribution 
mechanisms. They can provide an indication of user and supplier groups. Contextual data may 
allow the identification of influencing factors, and analytical comparisons between regions 
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may allow the identification of particular trends, ‘hot spots’, communities, and groups within 
communities. Retail price data, combined with other market data, may help us compare different 
market stages or levels, identify drug supply structures and their degree of competition, and 
also may allow us to estimate drug dealers, intermediation margins, intermediation costs and 
eventually profits.
Third, retail prices are fundamental to estimating the value of drug markets, which in turn is 
essential in evaluating the potential impact of the drug business either on other illegal activities, 
such as money laundering, or on the functioning of the legal economy.
Fourth, drug prices may help target resources and evaluate interventions. Indeed, some 
governments and agencies may use drug prices as the benchmark data against which to review 
their supply reduction strategies. We refer here in particular to increasing law enforcement and 
controls against the drug supply chain, in order to drive drug prices upward and therefore reduce 
drug demand. Within this perspective, prices are sometimes used as key indicators of success 
(DiNardo, 1993).
Finally, drug prices data have been extensively used by criminal justice agencies, in a number 
of countries, to assist state prosecutors and judges in helping them to decide matters relevant 
to prosecution and sentencing policies, and confiscation, and/or forfeiture hearings (assets 
recovery). They are also utilised by defence lawyers to challenge decisions made by prosecutors 
and judges. As such, price data provide fertile ground for expert witnesses.
Although good progress has been made in the last 15 years towards a better understanding of 
the nature of the relationships between drug prices on the one hand, and demand reduction, 
supply control, and enforcement activities on the other, these are still not fully understood. 
The collection of reliable and complete price data should be considered a necessary (but not 
sufficient) step in order to understand the complexity of these relationships in any detail.
European and other international data collection systems on drug prices
The EMCDDA has been collecting data on retail drug prices since it became operational in 1995, 
with a view to complementing information provided with other indicators on drug availability at 
user level and retail drug markets. Instruments to collect data on drug prices have evolved through 
the years. The current version (Standard Table 16, see Annex 1) requests minimum, maximum, 
mean and modal annual prices at retail level (per gram or per unit) for a range of illicit drugs 
(cannabis resin, cannabis herb, heroin, cocaine, crack, amphetamine, methamphetamine, ecstasy 
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and LSD). This table also asks for methodological details regarding the type of data collection 
system used, sampling methods, potential biases, etc. All EMCDDA reporting countries (27 EU 
Member States, Croatia, Turkey, Norway) are able to report on retail drug prices, although the 
information reported is not always complete and it may not always be fully comparable from one 
year to the next (mainly due to changes in the method of data collection). 
Since 1995, Europol has been collecting information on both retail and wholesale drug prices via 
the Europol network and the Europol National Units. A standardised template (updated in 2001) 
allows Europol to collect minimum, maximum and average prices of cannabis (resin, herbal), 
cocaine (including crack), opiates (opium, morphine, brown and white heroin), amphetamine-
type stimulants (amphetamine, methamphetamine, ecstasy), LSD, psilocybin, fungi, khat and other 
substances deemed to be of interest. Member States are requested to provide for each drug type 
the price per weight (1 gram, 1 kilogram) or per unit (1 000 tablets, 1 tablet, 1 strip). Europol and 
the EMCDDA have recently agreed to cooperate and exchange expertise and information on 
wholesale drug prices, with the aim of setting up a mechanism to collect these data. Therefore, the 
current data collection practice at Europol is under review. It is expected that Europol will collect 
wholesale prices at least once a year. 
The United Nations Office on Drugs and Crime (UNODC) has been collecting data on drug 
prices — both retail and wholesale — since the implementation of the Annual Report Questionnaire 
developed by the Commission on Narcotic Drugs. The collection of both retail and wholesale 
drug prices was also maintained in the latest (1999) revision of the Annual report questionnaire, 
which was geared towards reviewing the progress made in meeting the challenges set out in 
the Political Declaration adopted by the General Assembly in 1998, and aimed to monitor and 
increase global understanding of the extent and nature of drug abuse. Countries are asked to 
provide minimum, maximum and average/typical annual prices for a range of illicit substances. 
What is generally not known, however, is the way in which the data are collected and whether 
they are representative of the country as a whole (UNODC, 2008). 
Methods of collecting retail drug prices data in Europe and beyond
A review of the retail prices data submitted to the EMCDDA in recent years shows that different 
methods of data collection and sources are being used, although most data are generated by 
the police. For example, of the 29 European countries reporting 2005 retail price series in 2007, 
more than half (18) provided routine data on retail drug prices generated in one way or another 
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by the police, with some variation in the specific data collection methods used (e.g. intelligence, 
covert drug purchases, police informants); while five countries provided data based on both 
police sources and other sources, and seven provided series of retail prices data obtained from 
non-police sources, for example via methods such as user surveys. Details of the different methods 
used in Europe are provided in Chapter 3 below.
Outside Europe, a number of countries have also developed systems for recording retail drug 
prices. Australia, for example, has been collecting data on retail prices via several information 
systems covering various aspects of the drug phenomenon. Both the Illicit Drug Reporting 
System (O’Brien et al., 2006) and the Ecstasy and Related Drugs Reporting System (Dunn et al., 
2007) of the National Drug and Alcohol Research Center analyse trends in retail prices from 
the late 1990s onwards. Prices of different illicit drugs are reported by drug users interviewed 
for repeated surveys among injecting drug users and regular ecstasy users. These surveys were 
designed to provide information on a large range of topics, including drug use and patterns of 
use, risk behaviours, drug use related harms, and health problems, but also on issues related to 
drug markets such as drug availability, perceived purity, purchasing patterns, drug prices and 
changes in drug prices.
In the United States, there is a long tradition of drug price reporting, as seen in the reports from 
the National Narcotics Intelligence Coordinating Committee or the Regional Information Sharing 
System, including the Western States Information Network and the Middle Atlantic-Great Lakes 
Organized Crime Law Enforcement Network, although explanations of the methodology used is 
often lacking (Caulkins, 2007).
The US Drug Enforcement Administration (DEA) has also been recording information on drug 
prices, through its System to Retrieve Information from Drug Evidence (STRIDE), database, since 
the 1970s (Arkes et al., 2004; Arkes et al., 2008). This database was originally designed to 
control the inventory of drug acquisitions in the laboratories and provide data regarding the 
quality and quantity of the substances collected for judicial processes. Data are obtained from 
seizures, purchases, and other drug acquisition activities conducted by undercover agents and 
informants from federal and, in some locations, local law enforcement agencies. Information on 
the nature of the transaction (a purchase or a seizure), its date, the total amount paid (in the case 
of a purchase), the type of illicit substance, the quantity involved, the packaging and markings, 
and for most drugs its purity, is reported. One of STRIDE’s major strengths is that it contains a 
large number of ‘transaction-level observations across the country’, ‘recorded in a more or less 
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consistent manner over many years’ (Caulkins, 2007). However, it mainly includes samples 
sent to DEA laboratories for analysis, and therefore excludes most of the very large number of 
undercover purchases made by state and local police agencies. Since data in STRIDE are not 
collected for research purposes, they are likely to reflect law enforcement priorities and activity.
The Heroin Domestic Monitor Program, set up in the United States by the DEA, surveys street 
prices in a number of selected cities (28 in 2006). Throughout the year, law enforcement agents 
and their informants conduct street purchases of heroin (DEA, 2007). Samples collected are sent 
to a laboratory for analysis. The purpose is to get a picture of what is currently available (quality) 
on the street and at which price. Recorded information includes location, time of day, amount 
purchased, packaging, drugs mixed in, purity and chemical signature.
Why the present guidelines?
The analysis of the different international information systems on retail drug prices, and in 
particular of information provided by different European countries, shows that there is substantial 
variation in terms of methods of data collection on retail prices both between and within countries. 
This raises concerns over the comparability of data across Europe.
In order to address these issues, an expert meeting was held by the EMCDDA in October 2007. 
At the meeting, the experts — including representatives of Europol and the UNODC — examined 
the approaches used by 10 European countries (Belgium, Germany, Hungary, France, Ireland, 
Lithuania, Malta, Poland, Turkey, and the United Kingdom) in monitoring retail drug prices 
and differences in national reporting practices. They also discussed key issues related to data 
collection, including factors that can affect drug prices and on which systematic data collection is 
practically non-existent (e.g. drug quality, transaction size, setting, buyer’s experience). Moreover, 
the participants highlighted the need to draft guidelines for those collecting data on retail drug 
prices in the different European countries, so that data providers at the local/national level are 
more informed about the issues relating to retail drug prices, with a view to improving their data 
collection strategies and procedures. A number of participants volunteered to take part in further 
discussions and provide more detailed information on the data collection methods used in their 
own countries as case studies for these guidelines.
The structure of this Manual is as follows. Chapter 2 outlines the issues identified as important 
for data collection and analysis of retail drug prices at the October meeting of the EMCDDA, 
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and provides the context for the case studies presented in Chapter 3. Chapter 4 reviews some 
practical issues relating to data collection, management and analysis. 
These guidelines are an instrument for all those involved in the data collection of drug prices, 
specifically at the retail level, in Europe. They provide useful general suggestions and review the 
main methods of data collection in Europe. They do not comprise an exhaustive study, or a strict 
prescription to be applied in every context. Particularly in relation to technical issues such as 
sampling, consideration of the specific circumstances of the data collection and reference to the 
literature is required.
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Chapter 2
General data collection issues
After providing a tentative definition of ‘retail drug prices’, this chapter addresses issues related to 
the sampling of retail drug prices, both geographically and over time. It then discusses the various 
factors influencing retail price observations, both those related to the characteristics of the retail drug 
markets and those related to the characteristics of the products and the purchases. It concludes by 
suggesting a minimum set of variables to be included in any information system on retail drug prices. 
Definition — retail drug prices 
Retail drug prices refer to those transactions in which the buyer is the end user — the consumer — 
of the product.
However, operationalising this definition is fraught with difficulties. The weight of the drug is not 
necessarily a good indicator of a retail transaction. The fact that the drug has been sold/bought 
in a ‘user-unit’, for example a ‘dose’ or a ‘wrap’, might be a better indicator. Having said that, 
analysts will need to know what the ‘typical’ wrap size is before they can make an informed 
judgement as to whether the information under consideration constitute retail transactions. Clearly 
there are grey areas, and the following examples highlight some of the inherent difficulties:
1. A mother buys 0.2 g of crack for her teenage son.
2. A wealthy businessman buys 28 grams of cocaine for his own use.
3. A teenage student buys a gram of amphetamine with the intention of selling it at a profit, to 
four friends.
4. A middle-aged male crack dealer gives two rocks of crack to a young woman (which she 
consumes) in exchange for sexual favours.
5. An undercover police officer buys 0.1 g of heroin from a street dealer.
6. A young man buys six ecstasy tablets, which he consumes over a weekend. 
7. A dealer buys 2 grams of heroin, with the intention of selling half at profit and keeping the 
other half for his own use.
In examples 1, 3, 4 and 5, the weight of the drug (or, more accurately, the weight of the powder 
containing the drug) indicates that they are retail transactions but the definition proffered indicates 
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otherwise. In example 2, the weight strongly indicates that this is a ‘wholesale’ (1) transaction 
but the circumstances fit nicely into the definition of a retail transaction. Example 2, whilst not 
concerning a majority of buyers, is certainly not unrealistic. In example 6, the ‘doses’ could 
indicate either a retail or wholesale transaction. But again, given the circumstances, this particular 
transaction falls within the retail definition. Example 7 is confusing as the weight of the drug could 
indicate either a retail or wholesale transaction, and the buyer is both the end-user and would-be 
seller.
As shown in examples above there is clearly a grey area in instances where users buy for a group 
of fellow users, or where user-dealers re-sell to their friends, and questions will arise as to whether 
these should be recorded as retail transactions. 
Perhaps retail drug prices may be defined along the following lines: 
Retail drug prices describe those transactions where the buyer has purchased a drug: 
(a) for his own consumption; or 
(b) for the consumption of another, free of charge; or
(c) for the consumption of another without profit; or
(d)  as part of a test purchase or overt drug purchase operation intended to mimic (a), (b) 
or (c).
An additional difficulty is that some data collection methods, for example covert purchases, may 
not specifically target the retail level of the market, and therefore may not allow the researcher to 
distinguish between transactions destined for end users, low-end sellers or mid-level sellers. Such 
a distinction may have to be done at the analytical stage, by choosing a cut-off point of a quantity 
below which the recorded observations are categorised as retail transactions. A further discussion 
of cut-off points can be found in Chapter 4, where some examples are also provided. 
(1) ‘Wholesale’ is used here as a way of simplification to refer to transactions that are not retail. It should 
be noted, however, that the market does not have just two levels, and that there are many levels in 
between. It would be misleading to lump together observations from the ounce level wholesale and the 
kilogram level wholesale, as it is to lump together ounce level and gram level.
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Sampling retail drug prices
A set of innovative methods used to collect data on retail drug prices is described later in the 
guide. The application of formal sampling methods to the collection of retail drug prices is difficult 
if not impossible given the nature of illicit drug transactions. It is clear that the practical methods 
used to obtain estimates of retail drug prices rely on techniques that diverge from the theoretical 
or ideal methods of obtaining a representative sample. Nevertheless, it is worth considering a 
sampling benchmark against which the practical methods adopted can be referenced in order to 
evaluate possible biases. 
The starting assumption in this section is that a single estimate of the retail price of an illicit drug 
is required for a country for a period of time. The estimate would take the form of a summary (or 
‘average’ measure), and the exercise would be repeated over time to establish trends. Ideally, a 
method of sampling would be selected that ensures the sample is representative of the population 
in the sense that it is a microcosm of the population in terms of all characteristics that influence the 
price of the drug. 
Sampling theory shows that probabilistic or random sampling provides a basis for constructing 
a representative sample. The simplest form of probabilistic sampling, simple random sampling, 
would require a full list of all members of the target population, without duplicates, from which the 
sample is drawn according to a random process. More complex sampling methods may reduce 
the need for a full enumeration of the population, for example by grouping the population into 
clusters, though all require some level of enumeration of the population and the application of a 
selection process where the probability of an element being selected is known. 
In evaluating a sampling strategy it is useful to consider the relationship between the population 
from which the sample is drawn (the sampling population), and the population that it is intended 
to represent (the target population). By necessity, the sampling population will commonly be a 
subset of the target population. For example, the target population might be all illicit retail drug 
transactions within a country during a specific time period.  However, a random sample is drawn 
from the retail prices paid by users in treatment, who are identifiable and available for study. 
In statistical terms, the sample will not be representative of the population as a whole if users in 
treatment differ systematically from the target population in ways that affect the prices they pay. 
Take as a second example a representative sample drawn from a single city. The sample will not 
be representative of the country if the city and the country differ in characteristics that influence 
drug prices. 
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The literature suggests a range of factors that might influence prices, many of which are 
elaborated in the following sections. The question arises whether a single national representative 
retail price for each illicit drug is appropriate, or whether factors such as quality or purity of the 
drug, location of the purchase, access to price information, the relationship between buyer and 
seller, and season are important enough to favour a different summary price for each of a set of 
circumstances.
In ideal terms, to evaluate whether a set of prices is appropriate, data would be collected to 
allow the statistical comparison of prices. The sampling frame would be stratified according to the 
factors considered important, and random samples of a sufficient size drawn from each strata. 
This implies a more complex sample frame than for simple random sampling, making it an equally 
unlikely proposition. However, within the framework of possible data collection methods, it does 
highlight the need to consider a range of characteristics of the purchase and the purchaser other 
than price, and the importance of collecting this additional information. The collection of the 
additional information would allow comparisons to be made, which would provide interesting 
information even though they might not meet the strict sampling criterion.
As an example of how the method of data collection could influence the data, consider the 
differences between undercover purchases made by law enforcement agents and those made by 
users and ex-users. The former may target street suppliers and the purchasers might lack detailed 
market information, whereas the latter are likely to be able to reach less accessible suppliers and 
have a clearer understanding of the price structure of the market. These characteristics could lead 
to a systematic difference in the prices obtained by each group. If it were possible to compare 
prices obtained from each group useful working premises might be found despite the limitations in 
sampling methods.
Within probabilistic sampling, increasing the sample size leads to improvements in the precision 
of the estimates. It is, however, important to understand that where the sampling population differs 
from the target population, or a non-probabilistic method is adopted, increasing the sample 
size does not necessarily increase the level of precision. The sample may be drawn from a 
homogeneous sub-group of the population, the different factors that have an impact on retail drug 
prices in the population being ignored. Drawing a larger sample may simply generate more of 
the same type of observation, doing little to improve the estimate. The lesson here is that a large 
number of one type of observation is of less value if major sources of variation are neglected. 
The sampling/data collection methods described in Chapter 3 do not pretend to obtain 
statistically representative samples of retail drug market transactions. Each method may favour 
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(privilege/ignore) specific subpopulations. In practice the task is to understand what the data 
collected within each sampling method represent in terms of the spectrum of retail drug market 
transactions. Contrasting the practical methods adopted to an ideal benchmark can be useful in 
highlighting areas of possible bias and for future investigation. Given the complexity and hidden 
nature of the retail drug market, this in itself would be a major achievement. 
Geographical coverage 
It is important in any data collection strategy to be as representative as possible of the different 
types of location of retail drug markets, and at the same time ensure there are sufficient elements 
in the sample from specific geographical areas of interest. Indeed, national data will not 
necessarily be of use in characterising a local drug market and vice versa. 
On the one hand, if one wants to be able to use data on retail drug prices to characterise specific 
markets or communities or as strategic data for law enforcement responses and evaluation, 
national data are not sufficient. Indeed, data broken down by region or smaller administrative 
geographical units are then necessary. But being able to end up with such breakdowns means 
that they need to be collected with this objective in mind and sufficient elements drawn from the 
geographical areas of interest.
On the other hand, there are issues related to the unequal geographical distribution of retail drug 
markets on the national territory. For example, specific types of retail outlets for illicit drugs may 
be concentrated in specific locations in a few large cities only, while others may be typical of 
suburban or small towns. 
Attention should be paid to main trafficking routes, and to border issues, in terms of importation 
flows and drug tourism (crossing a border to get a better quality or a better price), as these 
may have an impact on the geographical distribution of retail points of sale for illicit drugs. 
Geographical distribution of retail outlets may also vary depending on the type of substance 
analysed.
Since retail drug markets are by definition local, there is a need to be selective geographically. If 
the goal is to monitor retail drug markets and track retail drug prices only, focusing on a selected 
number of cities and getting relatively high frequency data from a few sources in each may 
provide better information than getting relatively less data for more areas, which may not provide 
data as rich and might be too expensive to implement.
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Sampling over time 
Trafficking flows and retail drug markets evolve over time, together with criminal group 
associations and supply reduction strategies and practices, all of which interact with one another 
in a positive or negative fashion. Drug supply and drug availability at retail level may also 
observe seasonal variations linked to variation in drug use patterns, for example at music festivals 
or particular holiday destinations. It is therefore important to be able to track changes in retail 
drug prices over time.
Although final data may be presented as an ‘annual summary’ measure which is then compared 
over the years at national level or against any other geographical breakdown, it is important that 
there are as many as possible data collection points within the year to ensure that changes in 
the retail price over a given year are integrated into the ‘annual’ measure. Before designing any 
scheme for data collection in terms of sampling over time, it could be useful to review the potential 
seasonal variations and take them into account.
If the goal is to use price data to evaluate the responsiveness of drug markets to variations in law 
enforcement, policies, or other factors, it is important to collect data at a high enough frequency 
that short-term effects can be shown. 
It is difficult to recommend an ideal repetition scheme for data collection on an annual basis, as 
it depends on the resources available. Monthly data collection would be ideal, although it may 
be unrealistic in many countries. Quarterly would probably be feasible for most data collection 
methods, and would provide much more valuable information than a simple annual measure. 
An option could be for example to carry out a complete data collection exercise twice a year in 
numerous sites over a high number of transactions, while for every month in between recording 
only a few observations from a limited number of sentinel sites. However, it is very important that 
the methodology (e.g. interview with 10 first arrestees held at police station for questioning every 
month) remains identical over the years so that data series may be constructed and comparisons 
made possible. 
Factors influencing retail price observations 
It is possible to identify a number of factors that might influence the retail drug prices observed. 
This again raises the question of whether a single, summary average retail drug price is a 
reasonable goal or whether a typology or set of drug prices under different conditions would be 
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more realistic. Depending on the viewpoint, these factors might be considered as the outline of this 
typology.
It is important to remember, however, that obtaining adequate data to estimate prices for all of the 
factors of the typology is difficult if not impossible.  
Determinants of drug markets 
From an economic perspective, the availability and price of drugs are a result of the interaction 
between drug demand and drug supply. Changes in the number of drug users, drug use 
patterns, the incidence of new users, and the average quantities consumed per user, may all 
influence the demand for drug products and so their price. Similarly, supply factors, especially 
the unpredictability surrounding the availability of an illegal product, can influence the price. 
Proximity to main international trafficking routes, the relative influence of organised crime groups, 
the technical know-how and capacity of clandestine laboratories, traffickers’ strategies to create 
new markets, attract new users or shape existing markets by conquering new shares of the 
business, may all have an impact on how much of a substance is available on the drug market, 
and consequently affect its price. The technology of how trades occur between buyers and sellers 
is also important, as technological change in this regard can influence both sides of the market 
and hence price. In addition, law enforcement interventions against the supply of illicit drugs may 
also have an influence on drug prices, whether at retail or at a higher level in the distribution 
chain, particularly when they result in seizures of illicit drugs, the discovery of production sites, or 
the dismantling of organised crime groups. 
Determinants of drug markets 
Changes in determinants of drug markets — such as different aspects of the demand for illicit drugs, 
supply side forces including traffickers’ strategies and organisation, exchange practices, and law 
enforcement activities — may prove difficult to link directly to changes in drug prices. However, 
it is important that information on such aspects is collected and analysed, to better inform the 
interpretation of any price data at the analytical stage.
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Characteristics of the retail drug markets 
Besides these more contextual factors, other characteristics of the retail drug markets would be 
worth recording together with drug prices data, as they may have a substantial impact on price 
setting. 
Date and location 
Festive, seasonal, day and time variations may influence price directly or through other supply or 
demand factors. The exact location of the transaction is also an important variable to consider, 
as studies have shown that there is geographical variation in retail drug prices (e.g. Cadet-
Taïrou et al., 2008; Caulkins, 1995a), linked probably to distribution networks and to the lack 
of integration observed in drug markets. Even with smaller regions or cities, several studies 
have revealed that price dispersion is wide. This fact has been explained by the illicit nature 
of the business, which leads to syndicates composed of a small number of drug dealers. This 
market organisation may be explained by the need to reduce the risk of being caught by law 
enforcement agencies (Desroches, 2007). It is therefore desirable to record both the date and 
place (by a postcode area, for example) of each transaction. 
Market structure, market levels, and settings 
Information that would allow the researcher to distinguish between different markets and different 
market levels would be very important to collect. Information, for example, on the type of dealer, 
whether s/he is selling various products, the typical transaction size of this dealer, whether other 
dealers are used to sell smaller quantities in the same local market, or whether this is the most 
typical retail sale point that can be found in the vicinity would be extremely valuable. 
It is also important to record information on the setting itself, for example whether the transaction 
was made in an open drug scene, in a street market, or in a more hidden location such as a 
private house, and information about the type of access and delivery, and even information on the 
characteristics of a dealer’s typical clients (whether marginalised drug addicts, those in treatment, 
partygoers, the general population, etc.) would be worth collecting so that price data can be 
related to a certain type of market and those that are obviously not obtained from retail sale 
points be taken out at analytical stage. 
Buyer’s knowledge and relationship between seller and buyer 
Finally, an issue that has been described in qualitative studies as having some substantial 
influence on prices paid at retail level, and on which information would be highly valuable, is the 
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involvement of the purchaser/user in the market itself and their experience as a buyer, in particular 
the strength of their ‘connection into the distribution network’ (Johnson and Golub, 2007) — their 
knowledge of the actors, relationships with the dealers, knowledge of the expected quality of the 
product, ability to negotiate prices, whether they use particular selling points regularly, etc. (Berg 
and Andersen, 1993; Reuter and Caulkins, 2004; Costa Storti and De Grauwe, 2008). 
Products and purchases 
As for any licit goods, prices of drugs depend on the type and quality of the products themselves, 
and on the quantity being sold. 
Products 
It is essential to define carefully the drug purchased. It may be important to distinguish between 
types of a single drug, such as brown and white heroin, which usually originate from different 
sources, and differ in terms of purity and route of administration. Data providers should be aware 
of the confusions that may arise from the physical similarity of different products. For example, 
powder ecstasy may be taken for amphetamine, or crushed crack for cocaine hydrochloride, 
or brown heroin for white heroin because of a change in the colour. Confusion may also arise 
from logos or identification marks, or even from the street names used for different substances, in 
particular in the case of synthetic drug tablets. Some purchases may also involve mixed drugs. All 
of these confusions may result in errors in recorded drug prices and should be avoided as much 
as possible. 
Chapter 2
Characteristics of retail drug markets 
The standardised collection of a list of variables along with price data implies a quasi-survey, 
which is not the objective here. Nevertheless, the literature suggests these elements have a 
substantial influence on drug prices, which makes it important to consider their collection. Even if 
it is not possible to collect information for each transaction, it would be useful to characterise the 
most common purchases obtained from an information system. For example, if the data is always 
collected from an urban centre at night, by an ex-user, it would be useful to record that information.
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Quality and purity 
Issues related to the quality of the products sold at retail level, whether in terms of the presence 
of cutting agents such as diluents and adulterants, or in terms of percentage of pure substance 
effectively contained in the final product (or THC content in cannabis products), may also be of 
importance when it comes to prices. The issue of the quality and purity (or potency for cannabis 
products) of illicit substances is, however, fraught with problems: first, there is very rarely any 
systematic analysis of drug purity and of the quality of the products sold at retail level; second, 
there is probably a difference between perception and objective analysis in terms of the quality or 
purity of the product; and third, it is not always clear whether quality and purity are a factor in the 
price paid at retail level. It seems, however, that in some cases at least, expected purity is a factor 
in the retail price paid.
There is not much evidence that dealers and purchasers have a precise knowledge of the drug 
purity (or potency) of the illicit substances sold at retail level (Johnson and Golub, 2007). 
Researchers have suggested that since the quality of a drug cannot be readily assessed until it 
is consumed, which generally occurs after it has been bought, then it is not the actual purity of 
the product that governs the negotiated price, but the perceived or expected one (Arkes et al., 
2004; Goudie et al., 2007). For these reasons, illicit drugs are usually considered ‘experience’ 
goods. Reuter and Caulkins (2004) add that even at the time of their consumption the purity (or 
potency) of illicit drugs may not be estimated accurately; reasons for this may include for example 
the effects of cutting agents and/or the variability in individual responses to the drug, but also the 
particular expectations of the consumer and the context of use.
Although the role a drug’s purity plays in price-setting mechanisms is not entirely understood, it 
is still useful to collect this information. In particular it may be used to a) evaluate the health risks 
related to drug users, b) uncover patterns of supply and c) inform law enforcement interventions. It 
also allows comparisons with other markets, for example internationally, based on prices adjusted 
for the purity content of the substance.
Some countries, where there may be good information available on the retail purity of illicit drugs, 
may argue that there may be less need to analyse each transaction for purity (or potency). In 
addition, law enforcement officials in some European countries have reported that the purity data 
obtained from the analysis of large seizures — which is carried out on a regular basis — holds for 
illicit drugs sold at retail level as there is not much cutting between different distribution levels 
and therefore drug purity would remain relatively uniform across these levels. This was confirmed 
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by research findings in the US and the UK, for example (Coomber, 1997, 1999). However, if this 
were the case it would need to be verified on a regular basis, in order to detect any change in 
drug suppliers’ practices. In some European countries, however, significant differences seem to 
exist between the ‘wholesale’ and ‘retail’ purities, as reported in the UNODC’s Annual report 
questionnaire (Pietschmann, personal communication).
However, good data on drug purity (independent of price data) in a country, even if it may 
provide for adjusting prices in an aggregated form at national level, falls short when it comes to 
analysing price variations. Indeed, drug purity is a critical element for standardising drug prices, 
as is the size of the transaction, and without information on the purity of the product bought, it 
is difficult to assess whether variation may be due to market factors, transaction-level factors or 
to the quality of the good itself. The only way to get purity-adjusted prices is to uniformly collect 
(for at least a few small geographical units) information on price, amount and purity. Ideally, 
purchased products should be brought to a laboratory for analysis. 
Transaction size 
Other elements may determine retail drug prices, in particular issues related to the packaging of 
the products and the size of transactions, both in terms of currency units and quantities of product 
bought. 
The fact that retail transactions of illicit drugs are illegal in most countries means that they often 
take place in a hurry, to diminish the time of exposure to law enforcement. Consequently, they 
Purity (and potency) — standard measures 
The purity of heroin, cocaine, amphetamine and methamphetamine is the percentage of pure 
substance the sample contains. For amphetamine, white heroin and cocaine it is important to 
mention whether this percentage has been determined to the base or to the salt (a conversion from 
one to the other is then always possible with a view to standardising different data sets). 
For ecstasy tablets, purity should be expressed in terms of content in milligrams of MDMA base per 
tablet. 
The potency of cannabis products is determined by their content of ∆9-tetrahydrocannabinol (THC) 
expressed as a percentage.
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are commonly priced in round figures, because giving someone change takes time (Reuter and 
Caulkins, 2004). For example, someone may buy a ‘20 euros bag’, and the content of the bag 
may vary both in terms of quantity and quality. They may also buy a ‘1 gram bag’, although it is 
not usually a weighed gram, but a ‘street gram‘, which may vary, for example, between 0.4 and 
0.8 grams. Retail sellers and purchasers are not likely to know precisely how much product is in 
a retail purchase, or to weigh it; indeed, they ‘do not think about the amounts in scientific terms’ 
but rather use argot terms to describe the quality of the product, often on the basis of the effect 
obtained (Johnson and Golub, 2007).
Therefore, as much as on the nominal price paid for the product, it is crucial to record data 
on what was actually purchased — i.e. the content of a bag or a wrap in terms of quantity 
(and wherever possible, in terms of actual purity) so that more information is available on the 
distribution of retail purchases in terms of size. This data may also allow to account for quantity 
discounts at analytical stage.
The issue of ‘group buying’ is also worth considering. Many users prefer this strategy since it 
allows them to obtain quantity discounts (Johnson and Golub, 2007) and, at least in theory, 
means that only the buyer is at risk of arrest (2). We suggest therefore that any price data that is 
linked to group buying is recorded and analysed separately from other retail price data.
Mode of payment 
Research has shown that for certain products in certain types of markets, purchasers may pay 
not only in cash but also pay a part in cash and the rest in kind, either in services or in goods, 
or may exchange drugs for goods (e.g. stolen goods) or services (e.g. sexual favours, drug 
distribution services) without any transfer of money (e.g. Caulkins, 2007; Ingold et al., 1994; 
Murphy and Rosenbaum, 1997; Telfair Sharpe, 2001). Since it would be extremely difficult to 
suggest a standardised method to value services and goods offered in payment for drugs, it is 
recommended that those transactions for which the payment was not solely made in cash are 
excluded from data analysis. However, in order to assess the extent of such practices, it remains 
important to record these observations, even if they are then excluded from analysis later and do 
not count toward the target number of observations. 
(2) Of course, ‘group buying’ often means ‘bulk buying’ and so could attract additional police attention, 
which in turn could increase the likelihood of the buyer being arrested. In such circumstances, the buyer 
may feel compelled to provide the police with the names of the rest of the group in an attempt to reduce 
the risk of being prosecuted as a drug trafficker.
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Variables to record for each transaction 
The discussions above point to a long list of information that one would wish to collect in order 
to analyse drug prices and drug markets. Such an extensive data collection might fit well in a 
specific survey carried out on an ad-hoc basis or every n years, but may be difficult to insert into 
a routine monitoring system on drug prices, mainly because of resource limitations. It will be up 
to those implementing such a surveillance approach to determine, depending on why the data 
is being collected and how it will be used, what information should be systematically collected 
in addition to a minimum set of variables (see box). It is important to note at this stage that the 
choice of data collection will determine the type of information that can be reasonably obtained 
and monitored.
Additional information on the setting of the transaction, the seller, the relationship between the 
buyer and the seller, the method of contact for the buy, the experience of the buyer, etc. could 
also be collected in a systematic way, depending on the data collection method.
Minimum set of variables 
The following variables should be recorded for each transaction:
location; ▯
date; ▯
time of day; ▯
substance names (may record both the real name after analysis and the street names   ▯
of primary (and secondary) psychoactive substances);
physical form (e.g. powder, tablet); ▯
unit and/or packaging (e.g. 1 gram bag, 1 dose, EUR 20 bag); ▯
real weight (based on subsequent analysis); ▯
amount paid in local currency; ▯
whether payment was made in goods or services (for subsequent exclusion from   ▯
the sample);
purity/potency (based on subsequent laboratory analysis); ▯
whether it is bought for a group. ▯
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Legal issues related to data collection 
There are a number of legal issues to consider when collecting data on drug prices, in particular 
when carrying out overt drug purchases (see Chapter 3), as procuring and subsequent possession 
of illicit drugs may be unlawful in many European countries if not performed by duly authorised 
and appropriately trained law enforcement agents. Covert drug purchases (see Chapter 3) also 
carry legal risks, as law enforcement agents must be careful that they do not incite someone to 
commit an offence which that person would not otherwise have committed (3).
In some countries, provisions in the legislation may be utilised to enable medical staff or other 
authorised individuals to possess and transport illicit drugs for other purposes than the medical 
ones stated in law, and in particular for research purposes. These provisions would be applicable 
in cases where non-law enforcement personnel have purchased samples, or are provided with 
samples purchased by drug users, and wish to take them to a bona fide laboratory for analysis. 
In some countries, in the absence of any specific legal provision, researchers have made special 
arrangements with the police and prosecuting authorities that enabled them to buy drugs (either 
directly, or via an intermediary from drug users) and have them analysed. Such arrangements are 
usually dealt with on a case-by-case basis.
(3) The landmark case of Teixeira de Castro v. Portugal (1998) 28 EHRR 101 is of particular relevance 
here. In this case consideration was given by the European Court of Human Rights to issues pertaining to 
entrapment and undercover policing in the context of a conviction for drug trafficking.

3C
H
A
PTER 
TH
REE
3
C
H
A
PTER 
TH
REE
41
3
Chapter 3
Principal methods of data collection in Europe
This chapter provides a brief description of some of the data collection systems for retail drug 
prices that are currently in use in Europe, with a view to better understanding their specific 
objectives, the details of the methodologies employed, and their strengths and weaknesses. It also 
highlights examples of implementation. 
Overview of the principal methods currently in use in Europe 
A review of the retail prices data submitted to the EMCDDA in recent years shows that although 
most data are generated by law enforcement agencies, particularly the police, other methods 
of data collection and other sources are also being used. Indeed, some countries systematically 
collect data from non-police sources such as drug users or professionals working in drug treatment 
services, for example, or via surveys, or using qualitative methods such as focus groups. In 
addition, ethnographic methods based on direct observation by researchers have been used to 
collect data on drug prices. A number of countries use a combination of different sources and 
methods. While many countries have set up monitoring systems that are especially focused on 
drug prices, it is not unusual to find countries using data collection instruments that collect various 
types of data, amongst which are drug prices.
Overall, our intention in this chapter is not to recommend one particular data collection method 
over others, but rather to better understand what the observations recorded within each method 
represent. Indeed, none of the methods described below pretends to be able to provide a 
statistically representative picture of prices on the retail drug markets at a national level, and 
for that reason it is helpful to better understand what type of population they are more likely to 
reflect. In particular, it would be useful to try and identify the types of biases that might result from 
the data collection and sampling process. For example, in the case of covert drug purchases, we 
may assume that law enforcement agents systematically pay more than typical market participants 
as they are not among the dealers’ usual clients, but we may also assume that they pay very 
nearly the market price, otherwise the other parties to the transaction would realise who they 
are. Transactions targeted by law enforcement agents are often specific in terms of location, for 
example taking place in street drug markets that are more accessible, rather than indoor (private 
flats, nightclubs, etc.). Equally, surveys of drugs users, whatever the mode of approach, and key 
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experts’ opinions, may reflect only a segment of the population of buyers and be very specific in 
terms of the type of retail drug markets from which data on retail prices are obtained.
Different data collection methods (or tactics) may resort to different sources of information. 
Table 1 summarises methods currently in use in Europe to obtain routine data on retail drug prices. 
These methods are described in more details in the remaining part of this chapter. 
Table 1: Data collection methods and sources of information for retail 
drug prices
Main sources
Main methods/tactics
Drug users and traffickers (1)
Law enfor-
cement 
agents  
(LEAs)
Drug 
demand 
reduction 
profes sio-
nals
Not in 
contact 
with drug 
services
Clients  
of drug  
services
Arrestees 
and 
prisoners
Informants 
working 
for LEAs
Participant 
observation
Research X X
Questionnaires Surveys X X
Interviews Research, surveys X X X X X X
Interro gations by LEAs X
Intelli gence reports by LEAs 
based on interviews with 
users and traffickers 
X X
Seizing  
documents
Documents recording drug 
sales and purchases seized 
by LEAs
X
Eavesdropping Monitoring of drug traffickers 
conversations by LEAs
X
Covert drug 
purchases
Conducted by LEAs and 
interme diaries acting on their 
behalf
X X
Overt drug 
purchases
Conducted by researchers 
and interme diaries acting on 
their behalf
X X
(1) The term ‘trafficker(s)’ is used throughout the document for drug suppliers, including street-level sellers 
and traffickers acting in the upper levels of the drug distribution system.
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Covert drug purchases (by law enforcement agencies): test purchases 
For many years now, law enforcement agencies have been using a number of approaches 
to systematically track retail and wholesale drug price data in an attempt to improve their 
understanding of how international and national drug markets function and whether enforcement 
activity influences drug prices. Covert drug purchasing is one of these approaches, although its 
main purpose is not to obtain price data but to secure evidence against drug traffickers (1). Two 
categories of covert drug purchases may be distinguished: test purchases, which for the most part 
generate data on retail prices; and undercover buys, which generate data on wholesale prices. 
Undercover buys are not described in detail in these guidelines as this tactic is usually applied 
when law enforcement agencies are required to infiltrate a criminal enterprise in order to 
buy drugs in wholesale quantities. Moreover, they are generally considered to be a far more 
controversial tactic than test purchases because their defining feature is that through covert 
means law enforcement agencies create, or at least facilitate, a serious offence for which the 
defendant is prosecuted. Usually, an undercover buy involves significant effort and cost to set 
up, and because of the inherent legal risks often requires hands-on supervision from lawyers or 
highly trained and experienced law enforcement agency personnel. This is particularly the case in 
countries that recognise the legal defence of ‘entrapment’ (2). 
Objectives 
Test purchasing is a well-established tactic, which law enforcement agencies use to obtain 
evidence against retail drug traffickers (i.e. suspects committing offences that involve the supply, 
offer to supply, or possession with intent to supply a controlled drug, or offences akin to these). It 
is usually used in circumstances where other tactics (e.g. ‘stop and search’(3)) have been shown 
to fail or are likely to fail. As such, the retail prices data that is obtained may be considered a 
by-product of this tactic.
The tactic is used in many countries and has a long history. In the UK, for example, excise officers 
were granted the power to conduct test purchases of tobacco as long ago as 1842, while test 
purchasing of drugs by police officers can be traced back to 1869, following the enactment  
(1) It is interesting to point out that law enforcement in some other countries (e.g. the US) do engage in drug 
purchases that are not directly related to a legal proceeding or an arrest; this introduces the concept of 
law enforcement engaging in a monitoring activity, rather than just an enforcement role.
(2) See the glossary on page 103.
(3) See the glossary on page 103.
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of the 1868 Pharmacy Act. This Act placed restrictions on the sale of a number of drugs — 
described as Schedule A poisons — such as opium, cocaine and laudanum and the police, often 
in the absence of any specific powers, used test purchasing as a means of identifying those 
shopkeepers, chemists and druggists who were flouting the law. For their part, UK pharmacists 
have long been empowered to conduct test purchases. The Pharmacy and Poisons Act of 1933 
authorised the Pharmaceutical Society of Great Britain to appoint ‘inspectors’ — registered 
pharmacists — for this purpose. These inspectors were empowered to enter the business premises 
of a registered pharmacist or an authorised seller of poisons and purchase poisons for the 
purpose of detecting offences relating to their sale and supply. 
Test purchases are also referred to as ‘controlled buys’, ‘verification purchases’, ‘test buys’, and 
‘buy-bust operations’. In the context of these guidelines and in the absence of any satisfactory 
definition in the research literature or in the legislation of EU Member States, we may define the 
term as follows:  
‘The authorised purchase of any articles, controlled drugs, medicines or other substances, by 
an appropriately trained law enforcement officer (or agent acting on his/her behalf), whose 
true identity is disguised or concealed, for the purpose of determining whether or not an 
offence has been committed.’
The above definition takes account of the fact that law enforcement officers and their agents also 
purchase drugs paraphernalia (e.g. cannabis or crack pipes, and ‘cocaine kits’ often comprising 
a small pouch containing a metal tube, a razor blade, and a glass vial), medicinal products, 
intoxicating substances (e.g. solvents), alcohol, and tobacco from shops and pharmacies to 
determine whether or not they are complying with the various pieces of legislation that prohibit 
or otherwise control the sale of these items. The word ‘agent’ covers children and young persons. 
In the UK, children and young persons are often used to make test purchases of tobacco and 
alcohol from retail outlets.
Details of the method 
Briefly, test purchases involving controlled drugs are made by a specially trained law enforcement 
officer posing as a drug user. The officer’s involvement is authorised by a senior officer — in UK 
police forces, an officer of at least the rank of superintendent. Based on intelligence reports, the 
officer, pretending to be a genuine buyer, approaches the ‘target’ — a retail drugs trafficker — 
and buys a small amount of drug from him or her. The transaction, which takes only a few minutes 
to complete, is usually photographed and/or video recorded by a surveillance team. In light 
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of technological advances, it is now common practice in some countries for officers to wear 
concealed miniature cameras and audio devices to record the transaction. The benefits of this 
practice in terms of evidence gathering are obvious, but the practice is also risky since officers are 
sometimes frisked by suspects (Maynard, 1996). In the majority of cases, a ‘back-up’ team, will 
be located nearby to render assistance to the officer in the event that s/he is robbed, assaulted, 
or the intended transaction is otherwise jeopardised. In cases where the decision has been taken 
to arrest the trafficker immediately following the transaction, the arrest will be carried out by 
officers located nearby. Conversations between the officer and the trafficker will usually be kept 
to a minimum, and will invariably involve slang or even code. For example, in London, if the officer 
wanted to buy one rock of crack and one wrap of heroin, s/he will ask for ‘One white (the crack), 
one brown (the wrap of heroin)’. In Moscow, an officer wanting to buy a wrap of heroin will ask 
for a ‘check’ (чек) — a small wrap containing around 0.5 grams. Often, the test purchases will be 
carried out by law enforcement agencies from areas or regions far away from where the targets 
operate in order to reduce the risk of the agents being recognised (Maynard, 1996). Having 
secured the necessary evidence, law enforcement agencies can then choose to arrest those 
targeted at a time and place convenient to themselves. This reduces the risk of public disorder and 
injuries to arresting officers.
Against the backdrop of community concerns over the problems associated with highly visible 
street drug markets where drug selling is often blatant, and the growing recognition that traditional 
enforcement tactics such as ‘stop and search’ have little impact in terms of disrupting these 
markets, the UK police are now making greater use of test purchasing. In the last two decades, test 
purchase operations against street level drug traffickers, particularly those selling heroin, cocaine, 
and crack, have proven to be highly effective in terms of securing quality arrests and subsequent 
prosecutions and convictions. For example, test purchases conducted in the course of Operation 
Welwyn, which was run by Metropolitan Police Service (MPS) officers in the London Borough of 
Islington from 1991 until 2001, generated hundreds of arrests, the vast majority of which resulted 
in convictions for one or more drug trafficking offences. On a cautionary note, opposition may be 
voiced to test purchasing on the basis that the tactic may disproportionately target members of 
ethnic minorities or may infringes civil liberties (Jacobson, 1999). 
It is worth noting that in the UK there is still a lack of specific powers to conduct test purchases 
for controlled drugs. This is despite the fact that legislation dating back to the early 19th century 
recognises test purchasing as a viable enforcement tactic, and statutory powers dating back to 
the 1930s and the late 1960s have provided pharmacists and trading standards officers with 
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the means to use test purchasing to detect offences relating to the sale of alcohol, fireworks, 
intoxicating substances (e.g. glue), medicines, poisons and tobacco. The Misuse of Drugs Act 
1971, the UK’s principal drug control legislation, provides no such powers to the police. Nor did 
the Police and Criminal Evidence Act of 1984, which gave new investigative powers to the police, 
including the power to search body orifices for controlled drugs, or the Regulation of Investigatory 
Powers Act 2000, which regulates covert investigations, or, for that matter, the Serious Organised 
Crime and Police Act 2005, which again provided new investigative powers to the police and 
Serious Organised Crime Agency (SOCA) staff. The same observations hold for the tactic of 
undercover drug buys. As such, covert drug purchasing by the police, customs officers and SOCA 
staff has yet to be placed on a statutory footing.
Collecting price data from test purchase operations may be carried out through the use of a 
standard form designed to record information on the transaction itself and contextual information 
on the offender. This form may be filled in electronically by any of the law enforcement agencies 
involved in the case back at the police station, so that information is automatically compiled in a 
central database from which analysis can be easily carried out.
Strengths and weaknesses 
Test purchasing appears to be a viable method for obtaining objective and reliable retail drug 
price data. Law enforcement agencies are able to collect key information (drug type, weight and 
price) as well as other important variables, such as purity, location, time, and even information on 
buyer/seller relationships, which can be incorporated into any subsequent analyses. 
However, if countries decide to use test purchase data to track retail drug prices they need to 
ensure that their law enforcement agencies (primarily the police) have the capacity to conduct 
test purchases in quantities large enough to generate sufficient data for meaningful analysis. For 
example, in MPS test purchase records, only limited data is available for drugs other than heroin 
and crack cocaine. This is a reflection of the law enforcement priorities inherent in test purchase 
operations, but in principle other drugs could have been included. Indeed, it is essential to 
remember that test purchases reflect the priorities of law enforcement agencies in terms of illicit 
products but also in terms of the types of markets and actors targeted. For example, data on 
prices collected through this method may not all refer to the retail level of drug markets and this 
may have to be sorted out later on at the analytical stage.
A further consideration is that test purchase operations are expensive to run (at least in the short 
term). Having to deploy surveillance teams and having arrest teams on standby means that initial 
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expenditure is high. However, since available data (in the UK) suggest that arrestees are more 
likely to plead guilty, law enforcement agents are less likely to be injured, and there are fewer 
opportunities for the traffickers to make spurious allegations about fabricated evidence, it is 
possible that test purchase operations may break even or prove to be less expensive in the long 
term compared to other enforcement tactics.
Finally, it is essential to bear in mind that such operations require a lot of preparation and 
planning, identifying observation points, securing specialist equipment, and obtaining the 
necessary authorisation from senior officers.   
An example — National Covert Drug Purchase Database, United Kingdom  
Currently, there is no standardised procedure in place for collecting price data from test purchases 
in the UK. In part, this is due to the fact that the country does not have a national police service; 
instead there are over 50 separate police services. However, some of them, Avon and Somerset 
Constabulary and the MPS, for example, have developed efficient collection systems.
In the summer of 1998, following some exploratory work using data drawn from test purchases 
conducted in the course of Operation Welwyn, the first Test Purchase Database was designed in 
the UK (re-named the National Covert Drug Purchase Database in 2001) by the MPS
The database itself was developed in Microsoft Access format, and records were converted to 
Microsoft Excel for subsequent analysis. Each record, comprising four tables with over 100 fields, 
was designed to record the details of up to four purchases, (drug type, weight, purity, and 
price), the date the drug was purchased, the location of the purchase, details of the offender (full 
name, date of birth, age, place of birth, nationality, ethnic appearance, sex, home address and 
a summary of her/his criminal history), and additional details relating to the offender’s arrest, 
prosecution, conviction and sentencing. The database was located in the Strategic Analysis Unit 
(SAU) of the Criminal Intelligence Branch of the MPS at New Scotland Yard, London. 
Since details of all test purchase operations are recorded centrally at New Scotland Yard, it 
was possible to identify which Operational Command Units — police stations — had run these 
operations and therefore readily locate the prosecution files that they had prepared.  
The files contained a wealth of information in the form of witness statements by arresting and 
investigating officers and forensic scientists, arrest and charge sheets, interview records, personal 
details of the defendant(s), and copies of court papers recording the verdict and sentence. 
Missing or incomplete data (usually relating to the defendant’s nationality, full criminal history, 
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or whether s/he was a drug addict or otherwise using drugs), could be obtained by recourse to 
other databases, such as the Police National Computer. 
Based on the analysis (King, 2004) of 538 records, comprising nearly one thousand purchases, 
it was possible to describe trends in the mean unit price (price per gram) of heroin and crack 
cocaine over the period 1992 to 2003. Figures 1 and 2 show a decrease in both over the period. 
For comparison, unit prices of heroin and crack cocaine obtained by the MPS and two other 
sources (NCIS, the former National Criminal Intelligence Service; and IDMU, the Independent 
Drug Monitoring Unit) are shown. Whilst some of the NCIS data were gleaned from test 
purchases, the IDMU data relied on other sources, such as interviews with drug users.
Figure 1: Mean unit price of crack cocaine (1992–2003)
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Figure 2: Mean unit price of heroin (1992–2003)
The current MPS system, originally devised in 1998, refined in late 2005 and formally introduced 
in January 2006, is based on data drawn from a single form — the Covert Drug Purchase Form 
(CDP Form or Form 916) (see Annexes 2 and 3). This form is designed to capture information 
relating to drug type, price, and weight and purity (if applicable). Contextual information, such 
as the age, sex, nationality, ethnicity, and place of birth of the offender, and the date, time and 
location of the purchase, is also recorded. The electronic version of the form is completed by the 
Exhibits Officer (an experienced police investigator) whose task is to keep a detailed record of 
all exhibits (drugs, documents, money, etc.) seized by the police in the course of the test purchase 
operation. The completed form is then sent to New Scotland Yard where researchers or analysts 
scrutinise and validate the information recorded by cross-referencing to other databases and 
documents. Data is then entered into the Covert Drug Purchase Database.
Informants run by law enforcement agencies 
Informants (known as CIs, confidential informants, or as CHISs, covert human intelligence 
sources in law enforcements circles) provide a good deal of drug price information to their law 
enforcement agency handlers, much of which finds its way into the agency’s intelligence bulletins 
and other in-house publications. 
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Objectives 
Many law enforcement agents, particularly those working on drug squads or similar dedicated 
units, regularly ask their informants to provide them with up-to-date information on drug prices. 
Since many, if not the majority, of informants are drug users and drug traffickers, they are well 
placed to provide reliable information covering both the retail and wholesale levels. 
Details of the method 
In some law enforcement agencies, officers complete a structured or semi-structured questionnaire 
covering drug prices when they meet with their informants. This approach has certainly been 
used by police officers in the UK, particularly by the MPS. In the absence of a questionnaire, 
handlers will often include information on drug prices in the intelligence logs or reports that they 
are obliged to complete after meeting their informant. Although the identity of the informant is 
confidential, if not secret, the information relating to prices is often accessible to other police 
officers. As such, intelligence reports are potentially a rich source of information on drug prices. 
However, trawling intelligence reports for this purpose is laborious and costly. 
Strengths and weaknesses
For reasons given above, informants are well placed to provide information on drug prices. 
However, it has to be recognised that while many of them routinely provide reliable information to 
law enforcement agencies, a significant number are unreliable and are likely to give misleading or 
false information in an effort to obtain payment, either on a pro-rata basis or ‘lifestyle’ payments 
or in the form of a reward, or as a trade-off for the law enforcement agency helping them to 
avoid prosecution or a stiffer sentence, or simply to ingratiate themselves with a particular law 
enforcement agency. Thus they may give misleading information as to where a trafficker sits in 
the hierarchy of an organised crime group or criminal network — in general terms, if the informant 
is able to convince his law enforcement agency handler that the trafficker is near the ‘top’ of 
the hierarchy, then s/he increases the likelihood of receiving more money. Having said this, 
we are not aware of anything in the research literature that shows that informants are likely to 
give misleading or false information relating to either retail or wholesale drug prices. In fact the 
reverse seems to be true — police officers briefing test purchasers rely heavily on informants for 
information relating to prices, and based on practical experience and research this information 
appears to be reliable. 
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Interrogation of arrestees 
Law enforcement officers obtain a lot of information on drug prices in the course of their 
interviews — interrogations — with arrestees. While this information is readily found in prosecution 
files and crime reports in a number of countries, and often serves to inform decisions relating 
to the prosecution and sentencing of drug users and traffickers, it is largely unknown to what 
extent it is routinely collated and analysed by law enforcement agencies to add insights to their 
understanding of prices and accompanying trends.
Objectives 
As with test purchasing, drug prices data elicited in the course of interrogations is often a 
by-product of the investigatory process. These data can prove to be a rich source of information 
and, if recorded on crime reports in electronic form, are easily accessible for systematic extraction 
and analysis. 
Details of the method 
In some countries, information relating to drug prices is often included in either the arrest notes 
and/or interrogation records, and in many cases this information is then transferred to crime 
reports and other documents forming part of the case/prosecution file. In London, for example, 
this approach means that it is possible to compile drug prices data drawn from the Metropolitan 
Police’s CRIS (Crime Report Information System) reports, which can be readily accessed and 
searched by police analysts and researchers as they are in electronic form. Although there is no 
requirement for the arresting/investigating officers to record the information on prices on the CRIS 
(there is no specific field for this), officers often include the information on the DETS (details of 
the investigation) screen. Searching this screen and extracting the information is easy, although 
admittedly laborious. In addition, since details relating to the forensic analysis of the seized drug 
(type, quantity, and, where relevant, purity) are systematically recorded on the DRUG screen, it is 
possible to validate the information provided by the arrestee. As such, the system enables police 
analysts and researchers to conduct quantitative and qualitative analysis. Since it is possible to 
electronically access archived CRIS reports, drug prices can be monitored over many years. The 
system described has been used on many occasions to obtain price data on cannabis, ecstasy 
and amphetamine and arrangements are in hand to use CRIS to generate price data on illegally 
diverted methadone.
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It may be envisaged also that, as a specific means of data collection, the law enforcement 
officer in charge of the interrogation of the suspect fills in a form with information on retail prices 
obtained from the suspect. Forms would then be collected and analysed centrally. Although this 
approach would mean that law enforcement agency analysts and researchers were able to avoid 
the laborious process of having to access and trawl crime reports or prosecution files, it may 
be difficult to implement as law enforcement officers may not have the necessary time during 
interrogation for such data collection, and would have to be motivated and trained to collect price 
information. 
Strengths and weaknesses
Law enforcement agencies in many countries use arrestees as a main source of drug price data 
and generally it is considered to be reliable. However, consideration should be given to the 
following points; first, under interrogation, some traffickers, wary of asset confiscation, forfeiture 
laws, prosecution or sentencing guidelines, may lie about the wholesale or retail value of drugs  
in their possession. Second, in some cases where buyers suspect that they might have been 
cheated — ‘ripped off’ — as to the weight or purity of the drug, they may lie about the price 
they paid because they do not want to look naive or foolish in front of their interrogators. Third, 
sometimes arrestees, believing that they have bought a particular drug at a bargain price, later 
learn from investigating officers that they have been tricked into buying some other drug that has 
a lower market price. On occasions, arrestees realise that they haven’t bought a drug at all but 
rather some innocuous substance. Novice users hoping to buy ecstasy in clubs often fall for this 
ploy. At this juncture, it is worth stressing that these situations are not particular to arrestees under 
interrogation and may affect any data collection method described in this document. Fourth, 
retailers and wholesalers sometimes use an intermediary to buy drugs on their behalf and in 
some cases the intermediary may have duped them into paying more than the local market price. 
Fifth, on occasions, in ‘joint possession’ cases (4), some arrestees, covering up for their spouses, 
siblings, or friends, may elect to admit to possessing drugs which they didn’t buy and so have 
little or no knowledge of the price paid. It is very important to note that, unlike researchers, law 
enforcement agencies may have opportunities to validate price information given by arrestees in 
the course of interrogation. For instance, in cases where an arrestee provides information as to 
(4) For example, whilst searching a house occupied by three people, police find drugs, but it is not clear to 
them whether the drugs belong to one, two or all three suspects. Taking into account the circumstantial 
evidence, the police might well decide to arrest all three people on suspicion of possessing the drugs, in 
anticipation that additional evidence (e.g. fingerprints on packaging or confessions) will be forthcoming. 
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the price s/he paid for, say, 10 grams of amphetamine during interrogation and the subsequent 
analysis shows that the purity is exceptionally high, s/he could be challenged as to the reliability 
of the original price given (5). 
Overt drug purchases (purchases by non-law enforcement agents) 
While test purchases are conducted in a covert manner by law enforcement agencies (see 
above), they can also be conducted in an ‘overt’ manner by non-law enforcement agents, 
such as researchers. In these cases the person buying the drug does so for research purposes. 
Accordingly, there is no need for him or her to conceal their identity from the seller. But, as 
underlined below, overt drug purchasing is rarely used to obtain price data on illicit drugs. Legal 
difficulties compounded by the barriers researchers encounter when trying to access illicit drug 
markets go some way towards explaining why this is the case. However, this may be regrettable 
considering the type of information and the quality of the data which can be collected in this 
manner. 
Objectives 
As already stated, overt drug purchases are rarely carried out. Nevertheless, academic 
researchers such as ethnographers or sociologists have already implemented this kind of data 
collection with the aim of understanding the ‘cutting’ practices and the chemical content of the 
substances found on the street (Wendel et al., 2003). This method of data collection is more 
common for licit drugs, namely tobacco and alcohol. For example, some researchers carried out 
surveys on the illegal sale of tobacco and alcohol to minors (Arday et al., 1997; Willner et al., 
2000), in order to evaluate the facility with which underage consumers can obtain these products. 
In overt purchases of illicit drugs the objectives are quite different, although gaining a better 
understanding of the availability of the product may be one of them. Nevertheless, the main 
purpose is usually to obtain the toxicological characteristics of the substances used in the area 
under study, which presupposes that the products purchased in this manner are then brought to 
(5) One of the present authors (Monaghan) investigated such a case in the late 1980s whilst serving 
as a detective at Southwark Police Station in South London. Analysis showed that the purity of the 
amphetamine was way above the average street purity of the drug, and when the suspect was 
re-interviewed he admitted that he had paid around twice as much for the drug than previously stated. 
Chemical profiling of the high purity amphetamine — referred to as ‘base’ — linked it to batches that had 
been seized at the point of importation.  
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a laboratory for analysis. It can also be used to gather information about new and previously 
unknown substances. 
Price data for illicit drugs may be collected through these overt purchases, but once again it must 
be underlined that obtaining this information may not be the main objective of the method.
Details of the method 
There is no standardised method for carrying out overt purchases. In the case of licit drugs, 
namely tobacco and alcohol, the methodology used to perform such purchases is quite simple: 
youths are sent into stores to test whether they are able to buy tobacco or alcohol or not; or, 
more precisely, to check whether sellers ask for their ID card and whether they sell the tobacco or 
alcohol to them. Some ethical considerations surround the fact that minors are sent to buy these 
items, but one study showed that, a few years after having participated to the surveys, the minors-
collectors were less keen to smoke than others (Alcaraz et al., 1997). 
In the case of illicit drugs, the situation is more complex. The difficulty of the method rests on who 
is in charge of the data collection. If a researcher (or a team of researchers) carries out the data 
collection, they must have a good knowledge of the context, i.e. of the drug use and drug markets 
in the area. This method of data collection is relatively similar to participant or direct ethnographic 
observation. Indeed, in that case, the ethnographer is often accompanied by an informant who 
helps them to collect samples of substances. 
If someone other than the researcher carries out the data collection, a strict protocol must be 
written. These people could be medical staff, social street workers or even illicit drug users. 
Consequently the protocol has to be very precise about the information to be collected on 
location, the time, the area, the product, its weight, its price, some characteristics of the sellers, 
and so on, with data on the price of the illicit drug bought being only one element of the data 
collection exercise. This type of method may prove very useful to gather information on the 
contextual elements surrounding the drug purchases themselves. 
A final, but crucial, methodological point must be underlined here. If one of the aims is to link 
price data obtained via overt purchases to the toxicological analyses of the substances bought, 
then all specimens have to be analysed with the same method of gas chromatography and mass 
spectrometry.
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Strengths and weaknesses
Due to the multiplicity of cases and the lack of a strict methodological framework for the 
implementation of such overt purchases, the strengths and weaknesses of this method to obtain data 
on drug prices may prove difficult to assess. Nevertheless, we can highlight the following points. 
In particular, one of the strengths of this kind of collection resides in the fact that as price data are 
collected in the pure context of a purchase, they may correctly reflect the result of the bargaining 
game. What may also prove an asset of this method is that, in addition to price data, information 
may be obtained on the context of the determination of the price: location, time, characteristics 
of the seller, and so on. Last but not least, this method may allow toxicological analyses to be 
performed and data on prices linked with data on the real weight, purity and quality of the 
product.
The weaknesses inherent in this kind of data collection method are numerous but to be 
expected. It should be stressed that, depending on the sample, the dataset obtained is often not 
representative of the national picture; time trends can rarely be analysed, mainly because these 
data collection strategies are rarely repeated in time; and mobilising resources to obtain a large 
sample of price data can be time-consuming and consequently expensive.
An example — SINTES information system, France 
Launched in 1999, the French National Identification System for Drugs and Other Substances 
(SINTES) is an innovative scheme for gathering information on synthetic drugs based on both 
police/customs seizures and drug samples and questionnaires collected directly from users by 
social outreach workers (Giraudon and Bello, 2007). This system, coupled with the TREND 
network of the French Monitoring Centre for Drugs and Drug Addiction (OFDT), has recently 
extended its focus to all illicit drugs. TREND is an information system organised around a network 
of local coordination points in seven French cities spread over the national metropolitan territory 
(Bordeaux, Lille, Marseille, Metz, Paris, Rennes, Toulouse), using a common strategy for collecting 
and analysing information on drug trends. 
The SINTES/TREND system carries out ad hoc surveys on illicit drugs in order to monitor the 
toxicity of the substances found on the national territory and gain a better knowledge of drug 
users’ characteristics and contexts of use. The protocol of data collection is quite strict.
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TREND local coordinators are in charge of recruiting surveyors for SINTES following an 
agreement with the OFDT. Surveyors come from a range of backgrounds — social street workers, 
people involved in techno events, students, volunteers in charities dealing with prevention and 
harm reduction, nurses and doctors working in needle exchange programmes — in order to ensure 
that data collection is carried out in a variety of locations and settings.
The selection process ensures that those employed fit the aims and goals of the study. Training 
and briefings are provided both by the local coordinator and by the OFDT. Surveyors purchase 
the drugs from drug users. When a surveyor has to purchase drugs, the local coordinator delivers 
a daily (or longer) mission letter, specifying the date, the place, and the maximum number of 
samples to collect. The OFDT provides each surveyor with an official card that is valid for six 
months. Surveyors are registered by the Inter-ministry Mission for the Fight against Drugs and 
Drug Addiction (MILDT). In the case of an arrest, these documents may protect surveyors from 
potential prosecution, once police have verified their status. 
Each time a surveyor purchases a sample from a user, s/he fills in a questionnaire which, 
depending on the product and on the location and setting of the transaction, includes different 
items: characteristics of the product (price, amount purchased, origin, context of purchase and 
location), characteristics of the users, expected effect, how the drug is taken, potential health 
problems following consumption, etc.
The OFDT finances the surveys carried out by SINTES/TREND. Each time a surveyor provides her/
his local coordinator with a sample of a purchased substance and its associated questionnaire, 
s/he receives a fixed amount of money. Note that this payment is a lump sum so this is not a 
‘pure’ test purchase: it is only the questionnaire that provides information about the price and 
the quantity bought during the last purchase of the user. The main benefit of this data collection 
method is that we are able to cross-refer information on price and quantity with information on 
purity. Indeed, all samples collected are then sent to a laboratory for analysis. 
As an example, the results of a survey that used this data collection method to get a better 
knowledge of the potency of cannabis products used in France in 2004 are summarised here (for 
a more detailed report see Bello et al., 2005). The fixed amount of money given to the surveyor 
upon submission of a cannabis sample (herb or resin) was EUR 25. The size of the sample was 
set at a minimum of one gram in order to allow proper toxicological analysis. The price for one 
gram of cannabis was lower than the fixed amount of EUR 25, but this sum allowed the surveyor 
to be reimbursed for any other costs (e.g. transport costs) as well as motivate the cannabis user 
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to provide a sample of her/his product by paying them above the market street price for a gram 
of cannabis. For other products such as cocaine or heroin, the fixed amount is up to EUR 60 to 
EUR 90. In these cases, surveyors are supposed to collect a sample of 0.1 gram minimum for 
toxicological analysis (that means that the user providing a sample always received more than the 
expected market street price).
In 2005, 392 samples of cannabis were collected in six cities. Of these, 371 questionnaires 
were exploitable. User reports show that 46 samples were home-grown, 52 were received as 
a gift and 273 were purchased (of which two samples presented too many missing values). 
Figure 3 provides the price paid by users for their last purchase by type of cannabis product 
and class of weight. The sample was split into two classes to differentiate between purchases of 
less than 12 grams and those over 12 grams. Indeed, on the French cannabis market it is usually 
considered that 12 grams is the cut-off point to differentiate between purchases for personal 
consumption (under 12 grams) and purchases to be shared with friends or to be re-sold later on 
(dealing in order to reimburse this purchase).
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Figure 3: Price per gram of cannabis in France in 2005 by type of product and class of weight
Figure 4: Potency of cannabis in France in 2005 by type of product and class of weight
59
The median price per gram (black point on the figure) of herbal cannabis for a purchase of less 
than 12 grams was about EUR 6 (n=56) while for purchases over 12 grams it fell to less than 
EUR 5 (n=17; range of weight=20–200 grams). This discount effect (Caulkins and Padman, 1993) 
has also been shown for cannabis resin: while the median price per gram for purchases under 
12 grams is about EUR 4 (n=123), the median price for purchases over 12 grams fell to about 
EUR 2.5 (n=75; range of weight=15–500 grams).
Figure 4 shows the potency of the cannabis collected during this survey. The sample was split 
into the same classes of weight as for the price analysis. The median potency of the cannabis 
available on the illicit market in France was shown to range between 8 and 14 %. Note that 
herbal cannabis is more potent than resin and finally that the higher potency of herbal cannabis 
in purchases of over 12 is not statistically different to that found in herbal samples of less than 
12 grams (due to the small sample of herbal cannabis purchased in quantities over 12 grams).
Surveys of drug users 
It may seem obvious to directly ask drug users about prices paid at the retail level for illicit drugs. 
In practice, however, this is rarely done and surveys among drug users are not a common way to 
obtain information on retail drug prices. Some limitations inherent to user surveys on illicit drugs 
prices are outlined below and may explain why this data collection method is not often used 
although it can produce very interesting information. 
Objectives 
Surveys among drugs users usually address health, social and legal issues or take place in order 
to evaluate the health and social services targeting drugs users (McLellan et al., 1992), and 
therefore information on drug prices is not usually the priority of these surveys.
The objectives of such surveys may be multiple. User surveys are usually set up to obtain 
information on the health situation of drug users, in particular in terms of infectious diseases and 
whether they are infected by blood-borne viruses such as HIV or hepatitis, but also the degree 
of social marginalisation of the users and whether they have been involved with the legal system 
and how often, etc. As previously emphasised, user surveys can also be carried out as a tool for 
evaluating drug treatment services. In this case, they may describe trends in the particular targets 
the drug policies set up.
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In other words, specifically dedicated surveys on price data or the economic behaviour of drug 
users are rare. To our knowledge, in addition to the Antenna monitoring since 1993 in Amsterdam 
(Benschop et al., 2009; Nabben et al., 2008) and the French ENa-CAARUD survey carried out in 
France in 2006 (Toufik et al., 2008), only Bretteville-Jensen and Biørn (2003, 2004) have carried 
out a user survey in Europe to obtain data on retail drug prices — it addresses the economic 
behaviour of heroin users in Oslo. The three of them are described below.
Details of the method 
Surveys of drug users can be differentiated depending on the way they approach their sample of 
users. Users can be surveyed through self-reported questionnaires, or through interviews carried 
out by professional interviewers who will then fill in a questionnaire for each participant. 
Usually, the greater the sample of users included in a study, the better it is (6). There is not enough 
space in this guide to discuss issues surrounding sampling methodology, but readers can refer to 
Dorofeev and Grant (2006) or Turner, Lessler and Gfroerer (1992) for further discussion. In the 
same way, the formulation of the questionnaire is an important aspect to consider and requires 
some caution; for an overview of questionnaire theory, Foddy (1994) may be consulted.
Nevertheless, it is important to mention that questionnaires specifically dedicated to illicit drug 
prices are sensitive and must be well formulated. Indeed, questions related to economic issues 
and access to drugs (e.g. price, quantity) are relatively badly perceived by users, and sometimes 
also by professionals working in the field, for a variety of reasons. Users may be reluctant to 
provide information about their activities in the illicit drug market. For example, questions referring 
to the quantity of drugs bought last time and the price paid may seem extremely suspicious to 
illicit drug users and they may be reluctant to answer them. And drug professionals may also have 
their reasons for being suspicious about questions on drug prices and other economic issues in 
user surveys. Indeed, they may often be worried about the future use of the data collected. So to 
maintain the trust they have built up with drug users, they may be reluctant to ask them questions 
on drug prices, the quantities bought, etc.
A crucial point when questionnaires are elaborated is to avoid being too ambitious in the number 
of questions included in a survey and to keep the questionnaire to a reasonable length. Indeed, 
a long questionnaire may put respondents off, increase the risk of a low response rate, and may 
even provoke reluctance to participate in the future.
(6) See Chapter 2 for a discussion of sampling issues and sample size.  
61
Strengths and weaknesses
One of the main strengths of this kind of data collection is that it is those people most concerned 
with the price of illicit drugs at the retail level — the users — who answer the questions. The 
information can therefore be considered as relevant. So, if the sample size is sufficient, the 
information can be robust. Another advantage is that surveys are usually carried out according 
to a survey protocol (7) that then facilitates any replication of the survey in the future. Therefore if 
the survey is repeated over time according to the same protocol, comparisons may be made and 
trends over time analysed.
Most of the weaknesses of surveys to obtain data on retail drug prices from drug users are of 
course dependent on the quality of the methodology used. For example, a small sample may 
lead to a lack of robustness in the data obtained. A questionnaire that is not well organised, with 
questions formulated in a non-appropriate way, may mean a low return rate. This may be the case 
if the questions about the prices paid (and quantities bought) are viewed as ‘too intrusive’, and 
respondents become reluctant to provide answers; or if, in the same way, surveyors consider these 
questions to be intrusive and become reluctant to interview users. A further limitation is that these 
surveys do not usually allow a sample of the substances bought to be taken for subsequent purity 
(or potency) analysis, and therefore the quality of the products bought cannot be objectively 
related to the price paid.
An example — ENa-CAARUD Survey, France
The ENa-CAARUD survey was carried out in France at the end of 2006 and may provide an 
example of what can be done in terms of user surveys to obtain retail price data, and of the 
problems that may arise (Toufik et al., 2008). 
ENa-CAARUD is a survey carried out among drugs users recruited from drug treatment centres 
and harm reduction facilities (CAARUD). The survey was carried out in 114 centres across France 
during one week, and its protocol ensured that all drug users meeting the selection criteria and 
attending the 114 facilities during this week were included. The staff of the CAARUD had to 
interview all new users met for the first time during the given week and fill in a questionnaire. 
A total of 4 651 questionnaires were returned to the French Observatory on Drugs and Drug 
Addictions, which was in charge of the implementation and analysis of the survey.
(7) See the glossary on page 103.  
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A specific question was included about the price of the illicit drugs in addition to questions 
about respondents’ socio-demographic characteristics (gender, age, housing, income resources, 
education level, employment, etc), drug use behaviour (substances, route of administration, etc), 
current treatment (e.g. opiates substitution), and infectious diseases (HIV, hepatitis).
The question was formulated as follows:
Table 2: Question on drug prices, ENa-CAARUD Survey 2006
If these drugs were used in 2006: price in euros of the last purchase (for licit products, it refers to 
purchases on the illicit market)
Heroin Cocaine 
Crack  
free base
Subutex® 
Buprenorphine 
Arrow® 
Methadone
Moscotin® 
Skenan®
Ecstasy
1 gram 
Brown    White
1 gram One-dose rock 1 pill  
8 mg
1 pill 
8 mg
1 bottle 
60 mg
1 pill or  
60 mg capsule
1 pill or 
capsule 
 _ _ _  _ _ _  _ _ _  _ _ _  _ _ _  _ _ _  _ _ _  _ _ _  _ _ _
Note that the question asks about both licit and illicit drugs. Indeed, a lot of users sell the 
pharmaceutical drugs prescribed to them in the course of drug treatment (such as methadone and 
buprenorphine) on the illicit market (Fountain and Strang, 2003). In France, there is also a thriving 
black market for licit drugs such as Moscotin (8) or Skenan (9). This market is the result of these 
drugs being diverted from social security, physicians and pharmacists. 
It should also be noted that the question sets up a standard quantity for each product bought 
at the last purchase. The reason for this is that users could have been very reluctant to answer if 
information on the quantity bought had been requested. This may lead to a potential bias in the 
answers: indeed, we do not precisely know if the user, when answering the question, responds on 
the basis of her/his knowledge of the price per gram or if s/he converts the quantity and the price 
of her/his last purchase into a price per gram. 
Another difficulty raised by this formulation of the question is related to the units of quantity 
that are provided in the question. As regards licit drugs, several dosages exist: for example, 
Subutex (10) 4 mg, Methadone 80 mg, Moscotin 100 mg, etc. Consequently, prices on the illicit 
market may differ depending on the dosage available; this led to users having some difficulties in 
(8) The main active ingredient of Moscotin is morphine sulphate.  
(9) The main active ingredient of Skenan is morphine sulphate.  
(10) The main active ingredient of Subutex is buprenorphine. 
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answering this question. This problem was also raised in relation to cocaine in the form of crack 
or free-base. The unit of a ‘one-dose rock’ is rather unclear and several sources confirmed that 
the weight of a rock of crack was not standardised. Consequently, the answers about the price of 
crack obtained through this survey could not be used. The issue of the unit of quantity may also be 
raised for other illicit drugs: for example, a ‘one-street gram’ rarely weighs one gram, but instead 
about 0.8 g.
Of the 4 651 questionnaires returned, 2 617 did not provide any answer to the question on 
the retail price of licit and illicit drugs; therefore the response rate was 43.7 %. Among the 
respondents, the most quoted price was that of cocaine (50.7 %), brown heroin (37.5 %) and 
Subutex (27.9 %). The substances least frequently quoted were Buprenorphine Arrow (3.1 %) 
and methadone (7 %). Responses show that some users were able to provide a price for several 
products. 
As mentioned above, the crack prices data could not be used: the answers gave a range 
from EUR 1 to EUR 300 for a ‘rock for one go’. Some sources report that a rock of crack 
weighs 0.1 gram while others report that a rock may weigh up to 1 or 2 grams. The lack of 
standardisation (revealed by the data) did not allow us to use them.
Nevertheless, as an example of the results obtained, Figures 5 and 6 show the median prices 
(symbolised by a black point) of the drugs included in this survey. It should be noted that prices 
provided by users who specified that it was for another dosage (for example Moscotin 100 mg 
instead of 60 mg) have been included here. This inclusion did not lead to major changes in the 
results. However, absurd answers (outliers) have been removed from the sample, for instance 
when users were declaring that a tablet of Subutex® was worth EUR 300 while the median price 
in our sample was EUR 3. 
The data collected show that the median price of brown heroin was EUR 40 and that of white 
heroin EUR 50, while that of cocaine was EUR 60. The median price of a tablet of Buprenorphine 
Arrow, Moscotin, Skenan and Subutex was EUR 3; that of a bottle of Methadone sold on the illicit 
market was EUR 5, and finally, that of an ecstasy tablet EUR 5.
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Figure 5: Median retail price of brown heroin, cocaine and white heroin, 2006
Figure 6: Median retail price of some pharmaceuticals sold on the illicit market, 2006
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An example — The Oslo study, Norway 
This ongoing study started in 1993 with the aim of analysing economic aspects of the use of hard 
drugs. Detailed information on drug use, income and drug prices from active hard drug users was 
wanted and the only needle exchange service, which had opened in Oslo in 1988, was chosen 
as the place for recruitment. The needle exchange service was chosen because information was 
sought from as broad a group as possible. Drug users in prison or in treatment institutions were 
assumed to be less representative than the group currently active in the drug scene. In addition, 
memories of last-month activities are likely to be reasonably accurate, whereas people outside the 
drug market at the time of interview are usually requested to consider life-periods considerably 
further back in the past than this. The needle exchange hands out free-of-charge hypodermic 
syringes and condoms as a preventive measure against HIV, and is centrally placed in an area of 
Oslo where a lot of drugs are also sold. 
An interview session consists of two to three nights during which as many visitors to the needle 
exchange service as possible are interviewed. The sessions were first held on a monthly basis, 
then quarterly from June 1994 and currently there are two data interview sessions per year 
(March and September). People are approached for an interview after they have used the 
services provided by the needle exchange service. The interviews are anonymous, and it is not 
possible therefore to register the interviewees to help recognise them from one interview session 
to the next. Some individuals have probably been interviewed more than once during the whole 
study period, but not within the same interview session. Based on the high number of visits to 
the needle exchange service (on average more than 100,000 single visits and over 2 million 
syringes are handed out annually) and comparisons of sample characteristics to what is otherwise 
known about the target population, the sample’s representativeness is deemed to be fairly good 
(Bretteville-Jensen, 2003). By the end of 2008 more than 4,600 questionnaires were completed.
The mean age for the whole sample is 32.7 years (30.4 for females and 33.8 for males), an 
increase of 3.5 years since the study started. The youngest person to be interviewed was 16 years 
old and the oldest was 62. Females constitute 31.4 per cent of the sample.
Price data are obtained by differentiating between types of drugs and quantities. Individuals are 
asked specifically about prices of street units, one gram and five grams of heroin, amphetamine 
and cocaine and also about prices of cannabis, methadone and various tablets. Self-reported 
data may represent the heterogeneity of prices within the market and reflect the price discount 
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available to buyers who regularly frequent the same dealer. Dealers are asked how much they 
paid for the last quantity of drugs they bought (at least partially) for dealing. 
The market purity of drugs could be an important determinant of the price-responsiveness of drug 
consumption, and trends in market prices should ideally be presented in quality-adjusted terms to 
reflect the potentially important effects of purity changes on behaviour. Police seizures indicate 
that there is large variation in drug purity both on the retail and wholesale levels. The evidences 
of regular ‘cutting’ of drugs in the Norwegian drug markets are weak, however, as the average 
purities on the two levels are similar and seem, despite fluctuating trends, to follow each other 
over time. The purity is usually unknown to the buyer at the time of purchase so for some types of 
analyses quality-adjusted prices may not be very useful after all. In any case, it is not possible to 
collect purity data using this approach.
An example — The Antenna monitoring scheme, The Netherlands
Since 1993, Amsterdam Antenna has collected qualitative and quantitative data in order to 
document and analyse trends in substance use among adolescents and young adults in the city 
(Benschop et al., 2009; Nabben et al., 2008). Our qualitative panel study traces the latest 
developments by conducting individual, face-to-face interviews twice a year with a panel of avid 
nightlifers and professionals from various nightlife scenes. The focus is on trendsetters who try out 
new types of music, events, nightspots and drugs, or create new variations on older themes. They 
also lead the way as drugs or styles go out of vogue. Panel members report about consumption 
patterns, demand and supply within their own networks or scenes. 
Our annual quantitative survey delivers quantitative data about substance use in specific groups: 
school-going adolescents, young clients of youth services, cannabis coffeeshop customers, pub 
goers and clubbers. Questions on retail drug prices were included in the 2003 and 2008 club 
surveys and the 2005 survey of customers of pubs and cafés.
Other statistics reported in the Antenna monitor derive from sources we call substance use 
prevention indicators. These provide quantitative data on the alcohol and drugs market from 
several sources: requests for information or advice received via a telephone help line and 
a website; substance use education contacts at dance events; and results from the testing of 
voluntarily submitted drugs. The two most recent editions (2007 and 2008) of the Antenna 
monitor also include information of prices of ecstasy tablets submitted for testing.
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Panel study 
In the panel interviews trendsetters are asked about the typical price of drugs within their network. 
The common price for one tablet of ecstasy is EUR 5. A ‘wrap’ of cocaine typically costs about 
EUR 50 to 60. These wraps are supposed to contain 1 gram of cocaine, but some indicate that the 
doses are rather 0.9 grams.  
Table 3: Retail prices in Amsterdam, 2008
Substance Quantity Price range Typical price
Ecstasy tablets 
Ecstasy powder/crystals
1 tablet 
1 gram
EUR 3–5 
EUR 25–30
EUR 5 
EUR 25–30
Cocaine 1 wrap (1 gram) EUR 40–70 EUR 50–60
Amphetamines 1 gram EUR 5–30 EUR 10–15
GHB 1 vial (5 ml) EUR 1–10 EUR 5
Ketamine 1 gram EUR 30–50 EUR 35–40
Survey 
In the Antenna club surveys respondents were asked whether they had purchased ecstasy and/
or cocaine themselves from couriers (‘line couriers’ or ‘wrap services’ deliver drugs to your front 
door), home dealers (dealers selling drugs from their own home) or dealers in nightlife settings in 
the past year. And, if so, how much they purchased at what price.
In the 2005 Antenna survey among customers of pubs and cafés in Amsterdam, respondents 
were also asked about ecstasy and cocaine prices. However, no distinction was made between 
categories of drug dealers.
At least half of the recent (last year) users of ecstasy among the customers of clubs in the surveys 
of 2003 and 2008 had purchased ecstasy themselves. Between 2003 and 2008 the proportion 
of club goers buying from home dealers declined, while the proportion of club goers buying 
from couriers grew. Average retail prices decreased in all three categories of dealers. Prices in 
2008 varied between EUR 0.30 and EUR 10 per tablet; when one buys more tablets, one gets 
a quantity discount. Results show that the average prices are not very far apart. It is true that in 
2008 ecstasy in nightlife settings (EUR 3.62) was on average about 30 % more expensive than 
ecstasy from a home dealer (EUR 2.70), and about 10 % more expensive than ecstasy from a 
courier (EUR 3.32); but compared to the costs of a night out, the difference may seem negligible.
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Table 4: Retail prices of ecstasy (recent ecstasy users only)
Club goers 2003
(n = 144)
Pub goers 2005
(n = 70)
Club goers 2008
(n = 238)
Purchased ecstasy last 
year
Courier
Home dealer
Nightlife
Total
16.7 % 
44.4 % 
18.8 % 
 
55.6 % 64.7 %
22.2 % 
18.9 % 
17.6 %
 
51.1 %
Average price per 
tablet
Courier
Home dealer
Nightlife
Total
EUR 4.24 
EUR 3.51 
EUR 5.52 
 
EUR 3.15
EUR 3.32 
EUR 2.70 
EUR 3.62 
 
Like ecstasy, more than half of the recent cocaine users had purchased cocaine themselves in 
the past year. And, even more than in the case of ecstasy, the proportion of those buying from 
couriers increased while buying from home dealers decreased. Average prices were in 2008 
more or less comparable to 2003. Cocaine in nightlife settings appears to have become less 
expensive, but the number of club goers purchasing cocaine in nightlife settings is very small. 
When respondents ordered cocaine from a courier (the most common way of purchasing cocaine) 
they paid just under EUR 50 for 1 gram. The more they purchased, the lower the price per gram. 
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Table 5: Retail prices of cocaine (recent cocaine users only)
Club goers 2003
(n = 101)
Pub goers 2005
(n = 66)
Club goers 2008
(n = 156)
Purchased cocaine last 
year
Courier
Home dealer
Nightlife
Total
28.7 % 
44.6 % 
18.8 % 
 
60.4 % 63.6 %
40.9 % 
14.2 % 
4.8 %
 
55.0 %
Average price per 
gram
Courier
Home dealer
Nightlife
Total
EUR 48.79 
EUR 46.00 
EUR 52.89 
 
EUR 48.81
EUR 47.58 
EUR 43.10 
EUR 40.57 
 
Test service 
Consumers voluntarily submitting ecstasy tablets for testing with the Jellinek Prevention Test 
Service in Amsterdam are asked how much they paid for the drugs. About 80 % of the test service 
customers responded to that question. In 2007, prices varied between EUR 0.40 and EUR 7.50 
per tablet (depending on quantities purchased); averaging EUR 2.80 per tablet. In 2008, prices 
were very similar: between EUR 0.20 and EUR 10, with an average of EUR 2.84 per tablet. 
Interviews with key experts 
Interviews of drug specialists may prove to be a useful method for obtaining routine data on 
retail prices. This approach is widely used in social sciences either as the main method of 
data collection, or combined with other methods, for example surveys through self-completion 
questionnaires or participant observation. We may distinguish between in-depth individual 
interviews and focus group techniques, but one of the most important features of any qualitative 
approach is that it is based on the direct interaction between the researcher and a respondent or 
a group of respondents. Indeed, during the discussion, interviewers can move the conversation 
in any direction of interest they wish. This allows them to prioritise certain topics of research and 
eventually get more in-depth insight on particular aspects of interest. 
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Objectives 
Drug specialists — whether law enforcement or demand reduction professionals — can be useful 
sources of information on the retail prices of drugs in the illicit market. Different techniques may 
be used to collect information from them on drug prices. For example, the research methods 
might include: individual in-depth interviews, questionnaire interviews, focus group interviews or 
self-completion questionnaires. It might be useful to supplement any qualitative approach (e.g. 
individual in-depth interviews or focus groups) with self-completion questionnaires, which would 
allow the collection of data on retail drug prices per unit (per gram or per volume). This data 
could be analysed using quantitative techniques. 
Quantitative data collection techniques (e.g. questionnaires) may provide information on the drug 
prices themselves, while qualitative approaches (e.g. interviews) are generally set up to help 
understand changes in the drug scene as well as mechanisms of the illicit market. Such qualitative 
approaches are usually used to supplement the analysis and the interpretation of changes in drug 
prices. Repeated measurements can reflect trends in drug prices, although it is then necessary that 
the methodology used in the first instance is replicated (for example, the data may be collected 
during the same month in the following year).    
Self-completion questionnaires are a useful way to collect data from various sites and 
different settings when available resources do not allow interviewers to be sent everywhere. A 
questionnaire can be sent, together with instructions for its self-completion, to the targeted drug 
professionals. 
Details of the method 
Qualitative research methods are generally used to investigate the causes of a phenomenon. 
They are used to explain ongoing processes and obtain facts. They serve to answer questions 
such as Why? In what way? Much more rarely they address questions such as How many? or, 
How much? They are usually based on non-probabilistic sampling methods, and in particular 
may rely on a purposive selection of the sample — in general relatively small — that prevents the 
results from being statistically representative and precludes any extrapolation to the general 
population. The course of the interview is determined by the interviewer and the interviewee as it 
has an interactive character. In addition, it is important to note that the subjective approach of the 
researcher and their knowledge and experience are part of the data analysis process.  
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Individual interviews are a qualitative method based on a script that introduces topics to be 
discussed with an interviewee. The interview spontaneously reveals the interviewee’s way of 
thinking. Individual interviews show the interviewee’s individuality and eliminate group pressure. 
Individual interviews may be the only way to discuss the research issues with otherwise very 
difficult to access target groups. 
A focus group is a type of group interview that revolves around a single topic. The interviewees, 
purposely selected, are led by a trained moderator. The group in such interviews is small 
(6—12) and relatively homogenous. The very specific feature of focus groups is the use of group 
interaction in order to obtain information and more deeply analyse the topic discussed, which is 
far more difficult to achieve when there is no interaction between interviewees (Morgan, 1997). 
It is, however, important to recall that focus groups do not generate quantitative data that can be 
extrapolated to the whole population.
Appropriate research tools need to be prepared for conducting interviews, whether individual or 
group ones. In the case of individual in-depth interviews there is a need to draft some interview 
guidelines, while for group interviews a scenario is usually prepared. Audio recording may 
facilitate the transcription of individual interviews, while video recording is generally used in 
group interviews in particular as it helps to identify who said what.  
When setting out to collect data, a first step would be to list the institutions or agencies through 
which potential key experts may be reached. The drug specialists who are to be targeted need 
to have a relatively good knowledge of retail drug prices. One or more of these specialists 
should be identified in each of the listed institutions or agencies. Key experts or informants may 
come from one of the two following groups. Either they are drug demand reduction professionals 
acting in the field of drug prevention, harm reduction, treatment or rehabilitation — they may 
be therapists, medical service staff, prevention specialists or outreach workers. Or they are law 
enforcement agents working in the field of supply reduction and the prevention and reduction 
of drug-related crime — they may be officers from the police, customs or the military police who 
specialise in drug issues. Both groups can provide relatively similar information on drug prices. 
However, the thematic range of the interview might vary slightly. It is always better to interview 
key experts from both groups. Data on retail drug prices may be collected referring to the present 
but also to the past (e.g. last 12 months) and to the future (e.g. expected changes).  
In general, collecting data on retail prices is best done during an interview that deals at some 
point with the issue of the illicit drug market. For example, collecting information on the functioning 
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of the illicit drug market and ways of obtaining drugs by users may be an important background 
for the key information, which in this case is information about retail prices. It may also be worth 
touching upon issues related to the availability of different products on the illicit market as 
complementary information. Some of the topics that might be discussed may refer to changes on 
the drug scene, user supply venues, access to different products and ways of purchasing them. 
Moreover, it is sometimes possible to find out a lot of information about the different mechanisms 
of the illicit market and how it functions. The type of information obtained through interviews may 
be used as context for the main goal of collecting data on retail prices. For example, it is common 
to consider retail prices as one of the indicators of substance availability on the illicit market, 
and in the course of the interview it may be possible to discuss factors that might have recently 
influenced the fall, rise or stability of retail prices. Purity/potency and its potential relationships 
with prices may also be discussed during the interview.
As has been said, retail drug prices may be discussed during an interview, and in particular it may 
be the only way to get information on the typical amounts that are traded on the retail market for 
example. However, it may also be considered good practice to collect quantitative data on drug 
prices through the use of a questionnaire that is filled in by the interviewee(s).  
It should be possible then to report several or even a dozen retail prices; one may ask for example 
about the latest 10 or 15 prices observations in a given period. It might be the last month, the 
last two months or the last year. If the interviews are conducted on different dates it is useful to 
ask not about the last month but a selected month, so that repeated surveys refer to the same 
month in the year. Data need to be entered into a database so that quantitative analyses may be 
carried out and measures of central tendency and indicators of dispersion may be calculated (see 
pages 94 and 95 for more details). Data can also be collected from different regions. But before 
data collection, one of the most important issues is to define clearly the unit of weight or volume 
that prices should refer to. Indeed, there may be a lot of misreporting occurring if this is not done 
and properly clarified with the key experts before data on retail prices is collected. For example, 
in Poland a panel of experts was asked to provide retail prices per gram. However, later on the 
analysts realised that the prices they got referred to the traditional trade unit — ‘a bag’ in the case 
of cocaine, which contains between 0.4 and 0.5 grams. It might therefore be very important to 
collect data in the unit that is usually traded at retail level rather than ask for a conversion into a 
standard unit, as the latter may lead to reporting errors. Having a clear understanding of retail 
transaction sizes is therefore key to any research using self-completion questionnaires and should 
be integrated into the research preparation phase. 
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Strengths and weaknesses
While conducting an interview and analysing the data one must keep in mind that the quality of 
the information gathered in that way is highly influenced by the interviewee. 
For example in the case of the quality of the product discussed, it may be important to understand 
the basis of the interviewee’s knowledge on purity or potency: from forensic scientists, or from 
users. In discussing price data it might also be relevant to discuss the origin of the data provided, 
and any potential bias that may arise. For example, users arrested by the police may be inclined 
to raise or lower the price of the drugs they bought, for whatever reason, including sentencing 
ones. These are only examples, but interviews may also be used to discuss any of the potential 
biases that may affect the information provided.  
One of the main advantages of interviewing techniques is that they allow any doubts regarding 
the reliability of the information provided during the interview itself to be discussed. This is not 
the case in questionnaire surveys, where collecting additional information on the data provided 
is just not possible. Group interview participants might discuss each other’s information as well as 
reliability issues. This may be seen as an advantage of group interviews over individual interviews. 
Group dynamics make it possible to obtain a wider range of data. On the negative side, group 
dynamics may also push towards an artificial consensus as some of the participants may be too 
constrained by social pressure to refer to diverging opinions or behaviours. This may particularly 
happen when the focus is on very stigmatised behaviours. However, focus groups on an issue 
like drug prices should not be affected by such a drawback, as they would not refer to highly 
stigmatised behaviours, and because the participants are likely to be experts rather than drug 
users or drug dealers.
In each focus group there might be representatives of one institution (e.g. policemen) or of 
different institutions (e.g. a police officer, a therapist, a street worker or a doctor). Whether they 
are based on a homogeneous or heterogeneous group of participants, both approaches have 
their advantages and disadvantages. Having meetings of different service representatives in 
one group interview may allow different views to be obtained, each person displaying a slightly 
different approach to the topic under discussion, while an homogeneous group consisting of 
representatives of one service or one institution might allow data on specific aspects of the 
functioning of the illicit market to be obtained in a more detailed manner. For example, police 
officers may be able to discuss between themselves issues related to the influence of the 
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intensification of police activities on the rise or fall in retail prices, which they would not discuss in 
the presence of experts from harm reduction services or outreach workers. 
It is important to remember that the results of qualitative data analyses are influenced by the 
experience, the subjective approach and the knowledge of the researcher. That is why it is so 
important to refer to different sources and to be cautious when formulating conclusions.
An example — Project TREND, France 
The TREND network of the French Monitoring Centre for Drugs and Drug Addiction (OFDT) — 
(described in more detail on page 55) uses an approach based on group interviews to obtain 
information on new trends in illicit drugs markets. In each site of the network, two groups 
of experts are gathered together on a bi-annual basis: one group includes health experts, 
the so-called ‘health group’, while the other includes law enforcement officers, the so-called 
‘repressive group’. With a view to guaranteeing the quality of the group meetings and the use of 
the same procedure, the OFDT has written short guidelines based on three publications (Bloor  
et al., 2001; Sharken Simon, 2000; PNUD/Banque Mondiale/OMS, 1995).
During the meetings, interview guidelines are used. Only the guidelines for the ‘repressive’ 
experts group include issues on illicit drugs prices. In particular, experts in the group are asked, 
substance by substance, about the minimum, the maximum and the mean retail price of illicit 
drugs. There are also questions on different products’ availability and more general ones on 
the local situation of the illicit drug market. As the TREND network is composed of seven sites, 
a minimum of 20–25 groups’ reports are received per year. Price data collected through these 
expert groups are used as complements to price data collected in other ways, such as through 
ethnographic observation and/or user surveys. The supplementary data are collected because the 
level of retail prices shown by data collected via ‘repressive’ expert groups are often higher than 
those obtained through other methods. (The regular reports of the TREND sites can be consulted 
at http://www.ofdt.fr/ofdtdev/live/donneesloc/trendloc.html; they include the contributions from 
these focus groups.) 
An example — Central Bureau of Investigation survey, Poland 
The retail price of illicit drugs is generally considered an important indicator of the availability 
of a substance on the illegal market. It is also one of the indicators mentioned in the National 
Programme for Counteracting Drug Addiction 2006–10 in Poland. That is why the Polish national 
focal point on Drugs started to work on developing a data collection system that would improve 
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the quality of data in this field and make it possible to apply a unique procedure. The previous 
methods of collecting data on drug prices made it impossible to fully meet the reporting criteria 
set by international institutions and, what is more important, did not allow the analysis of trends 
in the availability of drugs. In 2006, thanks to the active cooperation of the Central Bureau 
of Investigation of the Police Headquarters, data on drug prices were collected according to 
a new methodology. The information was collected by means of a simple questionnaire that 
was completed by all Central Bureau of Investigation branches. There was a maximum limit of 
10 prices for each drug, and a minimum of zero.   
The data collected concerned retail prices, i.e. prices as practised in the street, not on the 
wholesale drug market. The information came from operational data, investigations, or police 
informants. In order to allow for comparability the data were collected within one specific month, 
i.e. Central Bureau of Investigation branches were asked to provide the 10 first mentions of retail 
prices for each drug that came to their knowledge within that specific month. Regional branches 
of the Central Bureau of Investigation sent the questionnaires to the Police Headquarters, which in 
turn reported them to the national focal point. The data were then entered into a database. In the 
course of consultations, prices that were simply not credible, whether too high or too low, were 
eliminated. The analysis also excluded the six observations of prices of white heroin, which were 
all lower than the price of brown heroin and therefore judged unreliable. The above situation may 
be indicative of the low prevalence of white heroin on the Polish market, which is still dominated 
by ‘kompot’ (home-made poppy product) and ‘brown sugar’. For the first time the modal price 
was calculated. It must be stressed that the exclusion of unlikely maximum and minimum prices 
from the database did not influence the modal and average values, which for most of the drugs 
remained the same. 
Other methods 
Other techniques are also used by law enforcement agencies, epidemiologists and social 
scientists that may prove useful in obtaining information on retail drug prices. They cannot, 
however, be put on an equal footing to those methods described above, since they may not 
provide routine and systematic data on retail drug prices.
Eavesdropping 
Eavesdropping is the term used to describe the action of listening secretly to the private 
conversation of others. Eavesdropping can be done over telephones lines (known as telephone 
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intercepts or wiretaps), e-mail, instant messaging and any other method of communication 
considered private. 
Telephone intercepts and other forms of eavesdropping are strictly controlled by laws and 
administrative directives and in most cases require interception warrants. The interception of 
drug traffickers’ telephone conversations provides law enforcement agencies with a wealth of 
information on all facets of illegal drug markets, including retail and wholesale drug prices. The 
fact that this information, or indeed any information, was acquired through telephone intercepts 
is rarely, if ever, publicly acknowledged by governments or law enforcement agencies. Having 
said that, there are occasions when information gleaned from telephone intercepts finds its way 
into the public domain. By way of example, British law enforcement agency drug intelligence 
bulletins have for many years listed wholesale drug prices, some of which were obtained through 
telephone intercepts.
Given the legal restrictions on eavesdropping in terms of authorisation and subsequent public 
disclosure of the information obtained, we recommend that this tactic is used only to supplement 
price data drawn from other sources. Moreover, because the tactic is used to obtain intelligence 
on criminals involved in serious crime, including drug trafficking at the wholesale level, it has only 
limited value in terms of generating retail price data.
Documentation seized by law enforcement agencies 
Since investigating officers often find arrestees in possession of documents detailing their drug 
sales and purchases, they are sometimes in a position to challenge price information obtained 
during interrogation by means of cross-referencing. Such documentation, sometimes in the form 
of a list of debtors, often provides the prosecuting authorities with evidence to support their 
allegations that the author is trafficking in drugs and not just using, or that s/he is a wholesaler, 
rather than a retailer, of drugs. Such documentation is sometimes adduced in evidence as part of 
asset confiscation or forfeiture hearings, but it is unlikely that prosecution files and crime reports 
are systematically updated with subsequent information that might contradict price information 
obtained at an earlier stage of the investigation. 
Occasionally, law enforcement agencies will arrest traffickers in possession of detailed ledgers, 
diaries or other documents that record multiple drug transactions, but the authors usually go 
to some lengths to disguise the product, weight and sometimes even the cost, using abstruse 
or esoteric words or terms. For example, the following entry: Butch 1/2 Whiz = 7 might well 
describe a transaction involving the sale of half a gram of amphetamine (Billy Whiz is a name for 
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speed) to a person named Butch (in all likelihood, a nickname or alias) for EUR 7. Or: 10 stones 
= 200 might refer to the sale of ten ‘rocks’ of crack cocaine for EUR 200. Obviously, deciphering 
transactions disguised in this way requires some expertise and investigating officers will almost 
certainly be obliged to persuade a prosecutor or a court that s/he has the requisite knowledge 
and experience to decipher such records before they agree that the officer’s findings form part of 
the prosecution case.
While documentation of this type often provides law enforcement agencies with valuable 
information on drug prices, which can be utilised to bolster the prosecution case that the offender 
is a drugs trafficker or assist the court in confiscation or forfeiture hearings, as a source of routine 
drug price data it has limited value. First, deciphering the transactions requires a good deal 
of time and effort. Second, many of the words and terms used will be open to interpretation — 
e.g. the word ‘blow’ could refer to cannabis or cocaine. Third, the information is often limited 
to a handful of transactions, and such documents are very rarely seized. Fourth, the contextual 
information (e.g. buyer–seller relationship, date and location of the transaction), is nearly always 
missing. In summary, price data gleaned from documentation is best seen as an adjunct to the 
other methods described in these guidelines.
General population surveys
It is possible to use general population (or school) surveys as a source of data on the price paid 
by drug users. The aim of such surveys is generally to obtain comparable and reliable information 
on:
the extent and pattern of consumption of different drugs in the population; ▯
the characteristics and behaviours of users; and ▯
the attitudes of different population groups towards drug use. ▯
The information gained is then used to assess the situation, identify priorities and plan responses. 
National population surveys have been conducted in the EU Member States in recent years. 
Some countries have carried out population surveys focusing on drug issues, sometimes repeated 
over time to analyse trends; while other have integrated questions on drug issues in more general 
health surveys, which may also be repeated over time. In both cases, however, although it is 
theoretically possible to include some questions on the price paid by drug users for their product — 
either the usual price or the price paid at their last purchase — this is rarely done in practice. 
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Population surveys usually include a set of questions, also called a questionnaire, which 
respondents are requested to answer either by themselves via a pen-and-paper procedure or via 
the use of a computer, or orally by responding to an interviewer in a face-to-face or telephone 
interview.
Compared to the other methods described above, the main strength of population surveys is 
that they can address a large and representative sample of the general (or school) population. 
However, there are a number of weaknesses that make population surveys of quite limited use for 
obtaining routine and systematic data on retail prices.
First of all, population surveys are costly and there is generally only a limited number of questions 
that can be included. In terms of drug issues, questions on drug use prevalence and attitudes 
towards drug use are usually prioritised over issues related to drug availability and prices. 
Second, population surveys are usually not carried out on an annual basis, and on average 
are repeated every three or four years. This means that data provided would have to stand as 
reference for quite a long time. This may not be an issue for products with a stable price, but might 
give a wrong or outdated overview of other drug prices, and would conceal annual changes in 
retail drug prices.
Third, questions on drug prices should only be addressed to those who have experienced a drug 
transaction recently. We can take as a proxy recent drug users, i.e. those reporting drug use in 
the last year, even if some of them may not have purchased the product they used. This points 
to the limitation of population surveys to capture uses that are not that prevalent in the general 
population. Indeed, although they may be able to obtain a reasonable sample of recent cannabis 
users, population surveys may not prove to be a good instrument for capturing a sufficient 
and representative sample of recent users of drugs such as heroin or cocaine. In other words, 
questions on price may only be relevant for drugs with a high number of last-year users.
Lastly, data on prices paid by users obtained through population surveys may also be rather 
limited in terms of the amount of contextual information collected. Indeed, the formulation of the 
questions may not allow information on the quantity bought to be obtained. This may prevent 
data on prices per unit of weight being produced, and will therefore limit comparisons with data 
from other data collection systems. In population surveys, the place and date of the transaction 
cannot usually be obtained either, meaning that the data on price cannot be qualified in terms of 
geographical distribution or variation over time. 
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Ethnographic observation 
Ethnographic methods may also be used to collect data on retail prices. As a general rule, 
ethnographic observations attempt to understand the subjective meanings and social contexts 
of people’s behaviour. In respect of drug use, or drug dealing, these observations allow the 
researcher to gain ‘first-hand’ experience of drug user (or dealer) behaviours and of the contexts 
in which these behaviours take place (Alvarez et al., 2003). In other words, Who uses? Who 
sells? Which drugs? How? In which context? are the main questions ethnographic research try to 
answer. The objectives of such ethnographic observations are usually very broad and therefore 
allow a wide range of issues to be covered. 
Ethnographic observation may allow some information on the price of drugs in the illicit market 
to be gathered, but also will give a better understanding of the economic burden borne by drug 
users, the practices surrounding exchanges between buyers and sellers, and the strategies used 
by dealers. 
There are different kinds of ethnographic observation methods: participant observation, 
direct observation and indirect observation. Participant observation is a period of intensive 
social interaction between the researcher and the subjects, which takes place in the subject’s 
environment (Alvarez et al., 2003). As the observer has to consider everything as if it has 
happened for the first time, anything can be subject to inquiry. In practice, a participant observer 
tries to see the world from the subjects’ point of view in order to understand their behaviour. As 
they are not regular participants of the environment, the observers must have a special training 
in observation techniques and sufficient knowledge of the drug phenomenon to be able to really 
understand what they are observing or what they are being told. Ethnographic observers must 
therefore be experienced in the field of illicit drugs.
Direct observation is either an open or an ‘undercover’ operation, and tends to be more focused 
than participant observation (Alvarez et al., 2003). It is a systematic and easy way of collecting 
data in order to understand drug-use and/or drug-dealing behaviours and the context in which 
such behaviours take place.
Indirect observation relies on the delegation of observation to some members of the population 
studied. These have to report both their observations and their experience to the ethnographic 
observer who then summarises them.
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Although it is difficult to standardise the methods used in ethnographic observation, it is essential 
for example to define correctly the target user group (young males, drug dealers, syringes 
exchange participants, etc.), and specify the location of the observations (techno scene, urban 
areas, workplace, etc.). The clearer the environmental information dealing with the group is 
observed, the higher the quality of the data analysis is later on.
Ethnographic observation may be a good way to obtain price data on several illicit drugs and 
on different geographical locations, and if observations are repeated, it may highlight time 
trends. However, covering a large geographical area (e.g. a national territory) and repeating 
observations over time may prove to be very expensive (in particular in participant observation). 
Indeed, such methods are usually implemented on an ad hoc basis or as a one-off exercise 
to get in-depth information and answer questions related to how and why rather than provide 
routine systematic information on levels and trends. All in all, ethnographic observation methods 
are difficult to replicate. Indirect observation may provide rapid assessments of price trends and 
other information relevant for characterising the availability and the potential diffusion of different 
substances. It may provide, for example, additional information on the perception of users of 
the quality of the products bought. It is important to recall, however, that these types of methods 
are highly dependent upon the quality of the observation itself (or upon the reliability of users or 
dealers in the case of indirect observation), since this determines the quality of the data collected. 
All in all, ethnographic observation should be seen as an interesting way of getting retail price 
data, and may be particularly useful in obtaining qualitative information about several market 
factors that may have an influence on the price paid. However, it is rarely implemented on a 
routine basis, mainly due to its cost.
Ethnographic observation is being used, for example, by the TREND network of the French 
Observatory on Drugs and Drug Addictions, covering in 2008 seven cities across the 
metropolitan national territory, to obtain retail price data along with other information on drug 
use and drug markets. Ethnographic observations are carried out in urban areas and the techno 
music scene by regular surveyors. These surveyors are illicit drug users, so they are well informed 
about the issues relevant to the research. Each ethnographic observer usually works with three 
or four users going to different locations of interest. At least one surveyor has to be a female. 
Users working for the network can be paid, but this is decided by the local coordinator. The 
anonymity of users is guaranteed. A key condition for the quality of the observations reported 
by the surveyors is that surveyors must not know each other. This restrictive protocol is seen 
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as a guarantee of the quality of the observations collected, and also means that a short-lived 
phenomenon can more easily be assessed. 
Here are some comments on the retail prices of cocaine collected during this project:
Currently, cocaine is sold at about 400 francs the retail gram. In two years the price 
was divided by two. The origin of the cocaine sold in Marseille is not clearly known. At 
present there is a problem resulting from cocaine availability: multiple injections ... 
(1999, Marseille)
A wide range of prices is reported, depending on the substance, the quality and the 
quantity bargained for. Users have mentioned a lower price: 100 francs per gram for 
a standard quality from Spain. ‘A yellow coke less than 200 francs’; ‘a good coke for 
250/300 francs on average, 400 francs maximum’. Cocaine, from Spain, brown, cut with 
amphetamines was reported in Toulouse in 2001. It is likely that cocaine coming from 
Spain is often cut with amphetamines.
 (2001, Toulouse)
Cocaine from EUR 40 to 60 per gram. The price is independent of the quality. At 
wholesale level, EUR 350 for 10 grams.
 (2004, Lille)
Among users frequenting needle exchange programmes, at retail level, cocaine is sold 
between EUR 50 and 80 per gram. The price can increase sometimes up to EUR 90. 
(2004, Paris)
Results of these ethnographic observations — based on both the reports done by ethnographic 
observers and on all the verbatim collected — showed for example that the median price of 
cocaine decreased from EUR 90 in 1999 to EUR 60 in 2001 and has remained stable since then 
(up to 2005). This trend confirms the trends in cocaine prices observed in France via the use of 
other data collection methods, namely user surveys and law enforcement intelligence.
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Chapter 4
General data management, reporting and analysis issues
This chapter deals with more practical issues of data recording and data reporting. It addresses 
what should be recorded and how, and provides some guidance in terms of data management 
and analysis.
Study protocol
Planning is the most important stage in ensuring good quality data, and occurs well before a 
single data point has been collected. At a theoretical level, the questions to be addressed, the 
information necessary to answer these questions and how to operationalise the collection of this 
information are decided. The data collection method, the desired output from the study and, if 
possible, the expected analysis should be specified. Careful thought should also be given at this 
stage to what format the data will take, how it will be stored, and what computing tools will be 
used for manipulation.
The study protocol should define carefully and unambiguously the items to be collected. This is 
of particular importance where the data is to be collected from non-standard sources or a range 
of different sources. For example, clear definitions of the variables are needed if they are to 
be drawn from arresting records, interrogation records, or any other law enforcement agency 
intelligence documents (see page 75 for examples) where a level of interpretation will be needed 
on the part of the data collector. Consideration of the discussion above relating to the definition 
of retail drug prices indicates how difficult deciding on a definition can be. Careful training and 
instruction may also be necessary to ensure those collecting the data understand the definitions. 
Products
A large variety of illicit drug products exist in the retail markets of Europe, with different 
names and brand names depending on factors such as chemical structure, origin, quality, and 
marketing strategies. The particular drugs available, used and trafficked in the local market, will 
determine which types and sub-types are recorded. However, for cross-comparability reasons, it 
is recommended that the substances for which retail prices are recorded, are at least classified 
under the following headings:
cannabis resin; ▯
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herbal cannabis (type unspecified): ▯
— sinsemilla;
— other herbal cannabis (European/non-European seeded herbal cannabis);
heroin (type unspecified): ▯
— brown heroin;
— white heroin;
opium; ▯
cocaine; ▯
crack; ▯
amphetamine; ▯
methamphetamine; ▯
ecstasy-type substances; ▯
LSD. ▯
Although there are broad categories covering all types of herbal cannabis or all types of heroin, 
it is highly recommended that one distinguishes, as far as possible, between different types of 
herbal cannabis and between brown and white heroin. The broad, unspecified categories should 
only be reported as a last resort when no distinction is available between prices of sinsemilla and 
other herbal cannabis (including both European and non-European seeded herbal cannabis), or 
between brown and white heroin.
Given the increasing number of growing sites involved in the domestic cultivation of cannabis 
in Europe, it would be useful, where possible, to distinguish between herbal cannabis produced 
domestically and that which is imported.
For heroin, although the distinction between white and brown is widely accepted, subtle 
differences in colour (e.g. ‘off-white’, ‘beige’, ‘grey’) may confuse the picture. 
As mentioned above, being able to classify all records under the suggested headings should not 
stop any country from using a more detailed classification where national or local interest support 
such an approach.
Selecting transactions from the retail market 
All the cases recorded should, in principle, come from observations (or estimations) from retail 
drug markets, as defined at the data collection stage. However, where this is not the case, there 
may be a need at the analytical stage to define a threshold quantity, observations equal to or less 
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than the quantity price being considered retail purchases and therefore retained in the analysis. 
Such a threshold will differ depending on the product.
Defining such thresholds is a very arbitrary exercise as drug distribution structures and levels are 
not fixed. They may vary greatly over time but also depend on the product, the criminals involved, 
the country, and many other factors. The size of the transaction may be the only indicator 
available. Particular caution is required when defining the purpose of a purchase based on size 
or cost alone. For example, some consumers may buy large quantities for their personal use while 
end-selling dealers may buy smaller quantities that they would then divide further, for example in 
one-dose bags, to sell to end-users.
Arkes et al. (2004), in their analysis of the STRIDE data in the USA, defined different classes 
based both on reasonably round transaction amounts that were relevant in the data they had, 
and on the need to retain from their sample a large number of observations in each class (end-
users, low-level sellers, mid-level sellers). They suggested the following cut-off points for retail level 
transactions: less than or equal to 2 grams for cocaine, less than or equal to 1 gram for crack and 
heroin, and less than or equal to 10 grams for methamphetamine and herbal cannabis.
For this exercise, for which we may only have information on the size of transactions, we suggest 
to consider the examples of cut-off points outlined in Table 6. They point to the maximum quantity 
(unadjusted for purity) threshold under which transactions would be considered as retail.
Table 6: Examples of cut-off points for retail transactions (in weight)
Cannabis 
resin
Herbal 
cannabis Heroin Cocaine Crack
Amphe- 
tamine
Metham-
pheta-
mine
Ecstasy LSD
UK 
(police) 3.5 g 3.5 g 1 g 1 g 1 g 5 tablets 1 unit
France 
(police) 3 g 3 g 1 g 1 g 1 g 5 tablets 1 unit
Poland 
(NGOs)
Experts contacted 
agree that 12 g 
would be too high, 
but do not suggest 
other weight limit
1 g 1 g 1 g 5 tablets 1 unit
USA 
(Arkes et 
al., 2004, 
STRIDE 
data)
10 g 1 g 2 g 1 g 10 g
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These data are based on the reactions that experts participating in this project got from testing 
a list of cut-off points in their home countries: these were set at 12 g for cannabis, 1 g for heroin, 
cocaine and amphetamine; 5 tablets for ecstasy and analogues, and 1 unit for LSD. They all 
agreed on the cut-off points suggested, except for cannabis products.
The above-mentioned thresholds are indicative rather than definitive standards. They are based 
on the comments from drug law enforcement agents in France, Poland and the UK regarding 
the maximum quantity involved in transactions that can be considered retail. They are not based 
on an analysis of empirical data on retail drug transactions, nor do they necessarily reflect 
prosecution policy practices; and therefore they should be treated with great caution.
Such cut-off points may vary between countries, and in particular may be set at a higher amount 
where the supply of specific drugs is larger and retail prices are lower. It is recommended that 
each country defines the cut-off points for retail transactions that are most appropriate to its 
market, based on an assessment of the average size of retail transactions for each substance.
Dealing with non-standardised units 
As suggested earlier, transactions may often be carried out in units or measures that are not 
standardised, in terms of both the amount of money paid and the quantity of substance bought, 
and conversion may be necessary. Whenever this occurs, it is always recommended that both the 
original measure in which the transaction was made and the standardised measure into which it 
was converted after applying a conversion rule are recorded. Conversion rules need to be clearly 
specified and applied in a systematic way across different data collection points and over time.
A further difficulty is that the quantity that is offered for sale (e.g. a 1 gram bag) is often different 
from the real quantity revealed by subsequent analysis. It is important to record both the quantity 
said to be sold and the true quantity, based upon subsequent analysis. For instance, both the price 
paid for a rock of crack or for an 1/8 oz of cannabis herb and the actual weight of the rock or of 
the 1/8 oz bag should be recorded if possible.
Although data should be initially recorded in the unit in which the transaction was made, there is 
a need at the analytical stage to standardise the different measures to allow comparisons across 
time and location. There is common agreement in Europe, and beyond, that retail prices data for 
cannabis products, heroin, cocaine, amphetamine and methamphetamine should be presented 
per gram, while retail prices of ecstasy-type substances and LSD are provided per unit (tablet, 
capsule, blot). Retail prices for crack are rarely collected in a routine way. Practices vary across 
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countries, with a few European countries providing prices per gram and a few others providing 
prices per rock. For comparison, it is highly recommended that retail prices for crack are reported 
per gram, since the size of a rock may vary substantially.
Data cleaning and construction of the data matrix
In this section we consider how the data should be cleaned and validated. This process takes 
place behind the scenes and commonly goes unreported; however, careful consideration of the 
accuracy and consistency of the data collected is essential prior to any analysis. 
A variety of ways in which to gather data on retail drug prices have been described, including 
interviews with experts and drug traffickers, the analysis of documents, overt and covert test 
purchases and the use of surveys. Given the variety of methods and the range of types of 
data collected, the suggestions here remain general, and should be supplemented by careful 
consideration of the specific characteristics of the collection method adopted and by reference to 
the literature related to that method.
The focus here will be on quantitative methods, though some comments will be helpful in the 
management of qualitative data.
Construction of the data matrix 
Once the variables to be collected are defined, consideration should be given to the nature of 
the likely responses and how they will be recorded in a data matrix. For quantitative analysis, 
commonly the data is transformed into a data matrix, rows representing observations and columns 
representing variables, with each intersection of row and column containing a data point. Ideally 
this data point should be a valid, in that it measures what it purports to, and reliable in that the 
measurement process generates consistent results, repeated measurement of the same or similar 
cases providing similar results. The data matrix is amenable to analysis using standard statistical 
or spreadsheet software. Once the matrix is formed, the data can be checked for inconsistencies 
within individual variables or for logical inconsistencies across variables. 
The data in the data matrix will come from one of the many methods of data collection. It is 
crucial to maintain a link between the original data source and an observation or row in the data 
matrix. A method of allocating a unique identifier to each data source/matrix row combination is 
necessary. This identifier must appear on the original data source and as a variable in the data 
matrix.
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Missing values should be considered prior to the collection of data. A large number of missing 
values suggest problems with generalising results. The characteristics of those observations with 
information may not be the same as those without information. It is useful to provide as much 
information on missing values as possible. Pre-definition of a set of causes for missing data is 
useful in some instances. For example, when entering data it would be useful to distinguish a) 
missing data in terms of no information on the data collection sheet from b) the question is not 
applicable to the person responding, and c) the respondent refused to answer. These values could 
be pre-coded and the codes applied to all variables:
99 — Missing
98 — Not applicable
97 — Refused to answer
The distinction between closed and open questions is useful in establishing the form of the likely 
responses. A closed question is one where the possible responses are limited and a set of options 
can be provided. For example, the variable gender will commonly have male or female as the set 
of possible responses. Closed questions are coded prior to any data collection. The researcher 
will decide how the set of responses are to be recorded, commonly replacing categories with 
numbers, e.g. male = 0 and female = 1. An open question is one where the respondent or data 
source is not limited in the information they provide. For example, in an interview a purchaser 
may be asked to describe where they purchase drugs and the response recorded verbatim. Open 
questions may be reported without coding, providing a qualitative response. Equally they may be 
coded after collection, a representative number of actual responses being used by the researcher 
to establish a set of categories in which all responses are placed, and which are then recorded in 
the data matrix.
Coding of questions provides a structure to the responses recorded in the data matrix. The coding 
of closed questions before the data is collected makes the data collection easier and can help 
avoid errors in the data entry process. However, it is important to realise that by pre-coding 
the possible responses recorded are limited, and information may be lost. Equally, coding is an 
example of how the researcher constructs data, and is a possible source of bias. 
Consider an example of a closed question. It is decided in advance to differentiate between 
purchases made within a city and outside of the city. Purchase is defined or operationalised as the 
exchange of money. A question may be posed on the data collection form as follows: Was money 
for the drug exchanged within the city? 
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The data collection form would include codes for the response. This may be pre-printed boxes 
for Yes and No, or instructions on the form may specify that purchases made within the city 
be entered as a 1 and outside as a 0. (Note that some possible complications relating to this 
question are definitions of the city, if part or all of the money was paid at one point and in one 
location, and if goods and services were offered instead of money.)
The same information could have been collected as an open question. A decision is taken to try 
to gain as much information on the location of purchase as possible, without pre-defining the 
answers. An open question might have been asked in an interview as follows: Where was the 
money for the drug exchanged? The information is recorded verbatim. The respondent is free to 
provide as much or as little information as they wish, including whether the purchase was made in 
the city or not. The researcher may report the entire response. Alternatively, the researcher might 
analyse the responses and code the location of purchase according to the answers provided.
The question could be made even broader. For example in an interview situation the question 
might be as follows: Describe the last time you bought drugs. The interviewer would be instructed 
to probe for important factors in subsequent questions, such as type of drug, quantity, location 
and the nature of the payment — in kind, in total, or on credit. The results would be recorded 
verbatim, and the response interpreted and coded by the interviewer at a later date.
A middle ground is a combination of a closed and an open question, the set of pre-defined 
answers being augmented with the option ‘Other’, and a second question that is answered only if 
‘Other’ is selected. Where the desired response is not in the list of options, the respondent selects 
the ‘Other’ category and elaborates in the second question.
Let us consider briefly how three variables of central interest — drug purchased, price and 
quantity — could be coded and recorded in the data matrix.
The information on drug purchased could be recorded in a text field in which the drug name is 
typed. The misspelling of entries and the use of non-standard slang or jargon would hamper the 
aggregation and comparison of the data. Statistical software would interpret the entries ‘cociane’ 
and ‘cocaine’ as two different categories, unless instructed that they were the same. Similarly 
‘speed’ and ‘amphetamines’ would be interpreted as two different categories.
For example, generating a frequency count on the following misspelt text entries would not 
provide useful results.
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Matrix entry Frequency count
Drug (text field) Drug Frequency
Cocaine Cocaine 1
Cociane Cociane 1
Hash Hash 1
Hashish Hashish 1
Resin Resin 1
Alternatively, if drugs were pre-coded the data may be held in a numeric field, containing 
the numbers 1, 2, etc., each number linked to a drug through entries in a data dictionary. It is 
common in statistical and database packages to store entries as numbers, and link the numbers 
to a set of labels for output. The benefits are that entries take less space to store, that sorting can 
be completed faster with numbers than words, and there are no issues of misspelt entries being 
treated differently by the computer package. The cost is that labels have to be applied before the 
entries are understandable.
For example, the same data which appears above could have entered the data matrix as follows, 
in which case the frequency count would be valid.
Dictionary Matrix entry Frequency count
Drug Codes Drug (Coded) Drug Frequency
Cocaine 1 1 Cocaine 2
Hashish 2 1 Hashish 3
2
2
2
Price and quantity should be considered together, as one without the other provides very little 
useful information. One solution for recording would be to enter the reported price paid and 
the reported quantity. The problem here is that where a range of sources have been used, the 
quantities reported may differ. For example, 10 grams, a half an ounce, a EUR 20 bag may 
all be reported quantities. To be comparable, a common quantity metric has to be found and 
the different values converted. Following the guidelines above, both the original unit and the 
converted values should be recorded in the data matrix.  
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As a general rule, if the original data can be recorded, any conversions can be made when 
necessary and checked. To make conversions and grouping easier, rather than using a single text 
field, split the quantity field into two parts, one for the amount and the second for the unit. 
Price 
(EUR)
Quantity Unit
20 1 bag
50 10 grams
70 0.5 ounces
For example, converting to grams:
Price 
(EUR)
Quantity Unit Conversion rate to gms
Converted 
quantity
Price per 
gram
20 1 bag 2 2 10
50 10 grams 1 10 5.00
70 0.5 ounces 28.35 14.175 4.94
As with any conversion, keep the original or most atomic data. For example, given a price per 
gram it is possible to allocate a price range to an observation. However, if we discard price per 
gram and kept only the ranges we could not reverse the process and construct the actual prices 
per gram for that observation. 
Validation procedures 
Care is needed when moving data from paper sources, such as questionnaires or interview 
transcripts, into a matrix in a computer file. Manual checks may be necessary to ensure the 
information is being correctly transferred to an electronic format. The first step is to review 
the rules for allocating a unique identifier to link a paper file to a computer record. Computer 
software can be employed to check for anomalies once the information collected is converted into 
a data matrix. It is important to maintain a record of how the data matrix has been constructed.
A data dictionary documents the structure of the computer file, listing the name and descriptions 
of each of the variables along with the labelling or coding scheme. Most statistical packages 
have the facility to print out this information once the data has been entered. The data dictionary 
is essential for anyone wishing to analyse the data.
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A data diary, documenting the results of any quality assurance checks, along with details of 
any data conversions and generally any measures implemented to resolve problems in the data 
matrix, should be maintained. If different data sources are integrated, it is important to document 
how this was undertaken. The logs available in statistical software and the queries established in 
database software can be used as part of this diary. This meta-information data will be invaluable 
if unexpected problems occur later in the process and as a service to anyone who uses the data.
Validating entries in the data matrix can be done either as the data is entered, or once the data 
matrix is constructed. Most computer packages will accept constraints on what can be entered 
into a field, thus identifying error values early in the process. Alternatively, once in data matrix 
form, it is relatively easy to check for missing, duplicate, unusual and out-of-range values. For 
example, a constraint could be set to prevent duplicate values being entered into the field holding 
the link between the paper file and the computer record. Alternatively, once the information is 
entered into a data file most packages have the facility to search for duplicates.
For categorical variables, frequency distributions can be used to identify missing and out-of-range 
values. Contingency tables or cross-tabulations can be used to identify inconsistencies between 
related variables. For example, a cross-tabulation of drug and unit of collection might be used as 
a logical check to ensure that quantities reported match the type of the drug. 
For continuous variables, such as price per gram, histograms or box plots are convenient methods 
of obtaining a summary of the information in a variable and identifying the presence of outliers.  
Data quality assurance should be carried out by a professional analyst with subject matter 
expertise and IT skills who can fully understand the implicit rules of the data.
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Cleaning drug price data 
When cleaning drug price data, consider the following: 
Manual checking of questionnaires, documents, records or transcriptions: 
Review and check inclusion criteria. ▯
Check missing data. ▯
Check data coding.  ▯
Database checking:  
Out-of-range values (data values that lie outside of the acceptable range). ▯
Missing values (omitted data). ▯
Errors (incorrect data values). ▯
Inliers (data value that lies within the acceptable range of values but is still an error). ▯
Outliers (data value that lies in the tail of the distribution of a set of data values). ▯
Duplications (the same record has been entered more than once). ▯
Inconsistencies (data values in different variables are contradictory). ▯
Transformations checking:
Check the data results after data recodes, conversion, weighting or other calculations. ▯
Integrating different data sources 
When integrating different data sources, consider the following: 
Check the database schemas (the structure of the different database and the ID of the records  ▯
should match).
Check for redundancy in the database (needless existence of attributes). ▯
Check for duplications (the same record has been loaded more than once, intersection of DB). ▯
Check for inconsistencies (data values in different attributes that are in contradiction). ▯
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Standard descriptive measures
Various descriptive statistics may be used to summarise price data, providing indications about the 
average, or central tendency, of the data set, and about the shape of the distribution of the prices 
in the sample. Care must be taken in selecting which summary measure to use as each of them has 
strengths and weaknesses, and provides different information.
Information on the number of observations used to construct a summary measure is essential. 
The number of observations on which published aggregated data on drug prices are based is 
rarely reported, perhaps due to the fact that in several cases such aggregated data are based on 
estimated prices by key experts (e.g. police) rather than on calculations derived from a number of 
observations. However, when disseminating final analyses on drug prices in a country, whether 
at regional or national level, it is crucial to always provide information on the total number of 
observations (or estimates) on which the results are based. Without this information it is impossible 
to judge, even informally, the scope of the data collection and whether there is any justification for 
extrapolating from the results to the nation as a whole.
The most common measures of central tendency of a data set (here a number of price 
observations) are the mean, the median and the mode. Descriptions of these measures and details 
of their calculation are available in Annex 4. 
In general, price data is likely to vary widely, with extreme values, low or high. Of the common 
measures of central tendency, the mean is the most susceptible to the effect of extreme values 
or outliers. The median, or middle value, is not influenced by extreme values, and neither is the 
mode, which is simply the most frequently observed price. It is recommended that both the mode 
and the median are reported for retail drug prices.
Some monitoring systems may only provide the ‘typical’ price as a central tendency measure. 
Commonly, the typical price is a price that is perceived as typical by the respondent; it is an 
estimate, and is usually based on individual knowledge of the markets and even experience in 
general, rather than on a number of specific observations. It may be constructed on the basis 
of the most frequently observed price (the mode), but not necessarily. Where a ‘typical’ price is 
reported it is important to provide information on how this value was reached.
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Although reported by some countries as a central measure, the value of the midpoint between the 
minimum and maximum price values is not useful and should be avoided, as it does not bring any 
new information (it is calculated as the sum of the minimum and maximum values divided by two).
Dispersion measures also allow characterisation of the distribution. Common measures of 
dispersion include the variance, the range, and quartiles. For measures of dispersion, again 
given the nature of the data, the minimum and maximum, along with measures of the lower (first) 
and upper (third) quartile would be useful. Descriptions and details of the calculation of these 
measures are provided in Annex 4. 
Reporting – from local to national
In the sections above, there was no specific mention of whether the analysis of the data, including 
the construction of the sample and data checking, should be performed at local or national level. 
In fact, it can be at either level, and this will depend mainly on the strategy of data collection and 
analysis that has been adopted in each country.
If a coordinated national strategy of data collection on retail drug prices is preferred, then all 
instruments to collect the data (e.g. protocol) and analyse them should be developed centrally 
at national level. This avoids duplication of competences and resources, ensures that the same 
tools are used and a uniform methodological approach is implemented throughout data collection 
and analysis. In that case, data collected at local level should be reported to a central national 
unit, which then carries out the analysis for all local data collection sites. The central unit should 
define a format through which the reporting of raw data by the local data collection sites is going 
to take place. It may be a database or an Excel sheet, depending on the number of records to 
be reported. This local reporting to the central unit may take place once a year, or at repeated 
time intervals during the year, or even continuously each time a new record is registered. Local 
data, before being reported to the central unit, need to be anonymised so that the legislation on 
data protection is respected. It is up to the central analysis unit to define the type and number of 
variables to be reported for each record (observation), but it may be rather limited (e.g. five or six 
variables). These variables may include, for example: price, quantity, product, packaging, place 
of transaction, date of transaction, method of data collection, type of retail market, etc.
Conversely, it may happen that in some countries, raw data are being kept at local level and that 
part of the analysis is carried out at that level. This may be the result of a non-harmonised data 
collection system with various data collection strategies being implemented at local level and 
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being left to the local initiative. It may also be that a uniform data collection strategy is applied 
throughout all local sites but that these sites are reluctant to provide raw data to a central unit. 
Whatever the reason, in that case, only aggregated data are reported to the central unit. It 
therefore becomes important, at a central level, to promote a unique methodological approach 
for analysis and reporting, so that all local sites come up with the same standard measures (e.g. 
median, mode), calculated in the same way. The central unit needs in particular to develop a 
reporting tool (either electronic or on paper) through which local sites can report the results of 
their data collection and analysis for each substance over a specific period of time. The forms 
should request, for each product, a minimum of information including the number of records 
analysed (sample size), measures of central tendency (e.g. median, mode), measures of dispersion 
(e.g. minimum, maximum), information on the sampling strategy, the method of data collection, 
and a characterisation of the retail markets targeted (likely biases).
Analysis at national level
A plan for analysis and outputs should be designed fairly early in the setting up of data collection, 
as this may have an impact on data collection strategies. For example, if comparative tables with 
retail prices at local level are to be prepared, there is a need to ensure that sufficient cases are 
recorded for each local unit to be adequately represented. Similarly, data entry formats may be 
conditioned by subsequent analysis.
An important issue to consider is the geographic distribution of the sample and how representative 
it is of the retail market transactions in that country. The problem becomes more pronounced once 
larger countries and complex systems of municipalities, districts and provinces are concerned. 
Should information obtained from a small village of a few dozen people count as much as 
information from a metropolitan area of a few million people? Should information from some 
remote rural areas — where drug use is often significantly lower — weigh as much as information 
from urban areas, where drug use and trafficking are concentrated? Should the information from 
a small province count as much as the information from a highly populated province?
As most of the data collection methods discussed above would not ensure a statistically 
representative sample of the retail market transactions in the country, adjustments at national 
level may be necessary to correct the sample. Although this may be quite straightforward when 
applied to samples of the general population, such a technique is fraught with difficulties when 
applied to drug markets that are illicit and therefore hidden, and for which characteristics are not 
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well described. We may think, for example, of applying some weighting factors to correct for the 
geographic distribution of the cases recorded. Ideally, the weighting should reflect the distribution 
of drug transactions in a country. But the issue here is about the choice of the index to be used in 
this weighting perspective; indeed, we would need to know the geographic distribution of retail 
drug transactions on the territory in order to be able to correct for any bias in the sample selection 
regarding this issue. As a proxy, one could use the distribution of drug use in a country. However, 
estimating the prevalence (total number of drug users) of drug use for a given drug, because of 
its hidden nature, is already a difficult exercise as it requires data that are often not available. 
Therefore, being able to map out drug users geographically appears even more problematic. 
Correcting the sample obtained for any distortion in its geographic distribution seems then very 
difficult, if not impossible, given our current state of knowledge of the drug markets in many 
European countries (1). Alternatively, if a decision has been taken to treat all information equally, 
the sampling design could be adjusted so that more price information is collected from potential 
dealing or trafficking hot spots.
Another question relates to the methods of dealing with missing data. It could be highly 
misleading if national prices only increase or fall because information from one province is 
missing or information from another province is being added. These issues have to be addressed 
at an early stage in the development of a national price monitoring system. In order to avoid such 
artificial statistical effects, there may be a need to establish clear rules for dealing with missing 
data (e.g. use of last quarter’s data as a proxy if new price data are not yet available).
A further issue relates to drug purity (or potency). Some may argue that the purity (or potency) of 
the drug products bought at retail level may vary greatly between retail outlets and that we may 
want to account for such variation. But in the absence of a monitoring system that records both 
the price of the product and its purity (or potency), current data on purity and potency are in most 
countries either not collected systematically or do not relate to the retail level of the drug markets. 
In general, price data at national level are not corrected for purity (or potency) as this is assumed 
to be quite uniform across the country — which is not necessarily the case. Thus, if systems exist in 
a country to determine the purity or potency of drugs, efforts should be made to link such data 
sets to price information.
(1) Although less satisfactory, the use of arrest data could be also considered; and if none of these 
breakdowns (drug use, drug arrests) is available, the population breakdown may be still a potential 
solution.
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Cross-validating the results obtained through different data collection methods and different 
sources should be carried out whenever possible. Indeed, it may allow data collection to be 
rationalised, i.e. knowing potential biases one could choose the most efficient method. 
Feedback to data providers
Feedback to data providers working in the field is crucial for both the survival and the 
improvement of each monitoring system, whether on retail drug prices or on any other matter, as 
this is fundamental in motivating those working on the ground without whom there would be very 
limited data collection.
Data providers may receive regular feedback on the progress of data collection within the country 
during the year. They may be asked to provide comments on an early draft of the analysis, so that 
operational and qualitative insights may be integrated into the final analysis before publication. 
They may all be invited to an annual meeting in which final results may be presented and trends 
discussed. This meeting may also be the right forum to review methodological issues and agree on 
future improvements in the monitoring system.
Besides national results, data providers may also receive some feedback about the use of 
their data sets in the international arena, and in particular be informed about the international 
organisations to which national data have been provided. They may be interested in international 
analyses in order to see how their country compares with others. In this respect, access to 
published international comparative tables on drug prices may be advertised; the EMCDDA 
comparative tables on retail drug prices may be accessed in its Statistical bulletin on its website 
(http://www.emcdda.europa.eu/stats09), and the UNODC makes its series on wholesale  
and retail prices available in the statistical annex of its World Drug Report annual publication  
(http://www.unodc.org/unodc/en/data-and-analysis/WDR.html).
Publication
Publication of the data that has been collected and analysed — in an aggregate form — is crucial. 
It is often the only way that data on drug prices are made accessible for use in policy evaluation 
and for research purposes. Drug price analyses may also be used in court. Publication allows also 
information from different data providers to be shared and may prove to be essential in enhancing 
comparative analysis at both national and regional level. 
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Results may have to be presented in different ways depending on the audience and the purpose 
of each presentation. However, whatever the variations in their presentation and in the level of 
details reached, it is important to ensure that there is always a way to access information on the 
methodology used to collect and analyse such data, as well as indication of the individual sources 
for different data sets, so that parts of the audience who are interested in these issues may access 
more detailed and technical information.
The issue of the confidentiality of the data should be addressed within the national legislation on 
data protection. As a rule, monitoring systems should only record individual anonymised data, 
and published data should only be presented in an aggregated form. Nevertheless, some data 
providers may still be reluctant to make their data public. They may argue they want to protect 
their sources, or may be afraid that their data indicate issues with law enforcement practices. It 
is also sometimes argued that price information should not be published, in order that it can not 
be misused by criminals. The latter argument, however, misses a key point; criminals in the drug 
market are very well aware of drug prices while enforcement authorities and policy makers are 
usually far less well informed.
Cross-country comparative analysis 
Although cross-country comparative analysis is not the focus of this document, a few issues related 
to drug price analysis at international level deserve to be addressed briefly so that national data 
providers may be better aware of such a challenge. Indeed, there are few adjustments that may 
be needed when carrying out cross-country comparative analysis. 
Variation of purity levels in the products sold in retail drug markets, if usually not taken into 
account in national data, should be accounted for when carrying out cross-country comparisons. 
Indeed, research shows that although the origin of drug products may be similar, there may 
be a high variation between different countries in the purity (or potency) of drug products sold 
in retail markets, due to several factors linked to both supply and distribution networks and 
law enforcement strategies and practices. Such an adjustment would allow one factor in the 
differential change in drug prices to be eliminated. However, adjusting retail prices for retail purity 
across different European countries may prove difficult in practice, since the purity (or potency) 
data that are available may not reflect the average purity (or potency) of drug products available 
on the retail market in all countries. Indeed, some countries in Europe do not systematically 
analyse drug products for purity (or potency) as this is not required in court. And for those who 
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perform analyses of drug purity (or potency), most of them are not able to provide purity (or 
potency) at different levels of the distribution system (retail, wholesale) as most analyses relate to 
all drugs seized, and some, even, only analyse seizures over a certain quantity. In addition, there 
may be other problems related to measuring purity or potency. For example, sampling of cannabis 
plants for analysis may vary greatly between laboratories — due to non-standardised practices 
in the way a field is sampled, and then in how parts of the plants are selected for analysis — and 
may lead to major differences in potency data.
Building up an average for several countries, for example a European average, based on the 
summary (national) retail prices in these countries may raise issues about the weight to give to 
each of the national prices in the European average and about the index that should be chosen 
for weighting national data. Indeed, giving an equal weight to each national data would mean 
ignoring the huge differences between countries in terms of size of the territory, total population 
and number of drug users. It is indeed commonly agreed that an index should be used to apply 
some weighting factors to national data. The total population of each country is often used for 
such a purpose, the implicit assumption being that the number of retail market transactions in 
each country is proportional to the total population of the country. This is, however, arguable 
as different illicit substances may be differentially available across European countries. In the 
absence of any indication of the distribution of retail drug transactions in Europe, another option 
would be to use the number of drug users per country and per substance as the index to calculate 
weighting factors for national retail drug prices. Precise estimates of the number of drug users, 
which would cover all types of users for each substance, are however difficult to obtain as they 
are fraught with methodological issues related to sizing a hidden population.  
Cross-country comparisons on trends over time may mean taking other precautions. For the 
purpose of building an international index, it is common practice to translate different currencies 
into a unique currency (here the euro), in order to make them comparable. However, when 
comparing indexes from several countries, it may be advisable to compare indexes based on 
prices in local currencies in order to avoid misinterpretations linked to variations in exchange 
rates. Adjusting for inflation is also a common practice when comparing trends in retail drug 
prices between different countries, so that one factor of differential change in prices may be 
eliminated.
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Entrapment
According to the American Law Institute’s Model Penal Code, entrapment occurs when a police 
agent ‘encourages another person to [commit an offence] by … employing methods of persuasion 
or inducement which create a substantial risk that such offense will be committed by persons other 
than those who are ready to commit it.’ (See Hay, 2003, p. 18). Entrapment is not a defence in 
English law; see R v Sang (1980) AC 402.
Law enforcement agents/agencies
Police officers (military and civilian), customs officers, and agents working for national drug 
enforcement agencies.
Stop and search
In the context of law enforcement agencies’ tactics to arrest drug traffickers, it refers to stopping 
the supplier in the street in the expectation of finding them in possession of drugs in quantities 
sufficient enough to justify arresting them for a trafficking offence.
Survey protocol
A protocol specifies the objectives of a survey and the exact methodology to be carried out (e.g. 
sampling strategy, sample size, population, questionnaire, etc); it is a reference document for the 
implementation of the survey. 
Value of the illicit drug market
It refers to the value of the total amount of illicit drugs consumed. This figure is usually obtained 
either by multiplying the estimated total amount consumed by the retail price, or by adding up the 
individual expenditures of drug users and the estimated retail value of the amount that is not sold. 
It is usually calculated as an annual measure and may be obtained for different illicit products 
separately.
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Notes on how to fill in Standard Table 16: 
General issues
1. Fill in one table (per file) for each routine statistic or ad hoc study providing data on prices of illicit drugs (do not report 
data from different sources in the same table); do not provide several tables in the same file, but one table per file.
2. Provide data on prices of illicit drugs in euros at retail/street level, corresponding to street level purity/potency.
3. In the absence of data collection and distribution of drug prices in your country, provide price estimates that may be 
available and mention how estimates were made in the methodological comments below.
4. For countries outside the euro zone, use the exchange rate (ER) of the data collection period to convert drug prices into 
euros; provide in the table the value of the (average) exchange rates used (national currency x ER = euros). Prices for 
a certain date should be converted into euros using the exchange rate of that date. Prices for a certain period of time 
(weeks, months) should be converted into euros using the average exchange rate for that respective period. Annual 
prices should be converted into euros using the average exchange rate of that year. Monthly exchange rates can be 
consulted at: http://europa.eu.int/comm/budget/inforeuro/.
5. Check for inconsistencies with data previously submitted to the EMCDDA by your national focal point.
6. Provide information in the methodological comments below; this is essential to carry out an analysis of prices of illicit 
substances at EU level.
7. Where methodology varies from one year to another, mention these changes in the methodological comments below.
Substances
8. For cannabis products, heroin, cocaine, crack, amphetamine and methamphetamine, provide prices per gram of 
substance sold at retail/street level.
9. For ecstasy-type substances and LSD, provide prices per tablet/dose/unit sold at retail/street level.
10. Ecstasy-type substances include MDMA, MDEA and MDA.
11. Distinguish as far as possible between different types of herbal cannabis; prices of herbal cannabis (type unspecified) 
should be reported only when no distinction is available between prices of sinsemilla and other herbal cannabis 
(European and non-European seeded herbal cannabis).
12. Distinguish as far as possible between brown and white heroin; prices of heroin (type unspecified) should be reported 
only when no distinction is available between prices of brown and white heroin.
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Statistical measures
13. The sample size refers to the number of samples for which prices are provided in the table.
14. The minimum value refers to the lowest price among all prices reported (to nearest EUR 0.1).
15. The maximum value refers to the highest price among all prices reported (to nearest EUR 0.1).
16. The mean value refers to the arithmetic mean (or simple mean), calculated as the sum of the prices divided by the 
number of prices reported (to nearest EUR 0.1).
17. The mode value (or typical value) refers to the most frequent price (to nearest EUR 0.1) among all prices reported.
18. Provide as far as possible the statistical measures mentioned above; should you not be able to provide these values but 
are able to provide other measures (such as the weighted mean or the median), specify it clearly in the methodological 
comments below.
19. The value of the middle point between minimum and maximum price values is not useful; do not use it under the 
headings ‘Mean’ or ‘Mode’.
Annex 1
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Standard Table 16: Price at street level of some illicit substances (EUR)
NAME OF THE DATA SOURCE (name of institution and name of monitoring system/study):  
COUNTRY:
YEAR: 2004 2005 2006
EXCHANGE RATE (4): ER = ER = ER =
Sample size 
(13)
Minimum 
(14)
Maximum 
(15)
Mean 
(16)
Mode 
(17)
Sample size 
(13)
Minimum 
(14)
Maximum 
(15)
Mean 
(16)
Mode 
(17)
Sample size 
(13)
Minimum 
(14)
Maximum 
(15)
Mean 
(16)
Mode 
(17)
Cannabis resin (1 gram)
Herbal cannabis (type unspecified) (1 gram) (11)
— sinsemilla (1 gram)
— other herbal cannabis (European/non-European seeded 
herbal cannabis) (1 gram)
Heroin (type unspecified) (1 gram) (12)
— Heroin brown (1 gram)
— Heroin white (1 gram)
Cocaine (1 gram)
Crack (1 gram)
Amphetamine (1 gram)
Methamphetamine (1 gram)
Ecstasy-type substances (1 tablet/unit) (10)
LSD (1 dose/unit)
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Standard Table 16: Price at street level of some illicit substances (EUR)
NAME OF THE DATA SOURCE (name of institution and name of monitoring system/study):  
COUNTRY:
YEAR: 2004 2005 2006
EXCHANGE RATE (4): ER = ER = ER =
Sample size 
(13)
Minimum 
(14)
Maximum 
(15)
Mean 
(16)
Mode 
(17)
Sample size 
(13)
Minimum 
(14)
Maximum 
(15)
Mean 
(16)
Mode 
(17)
Sample size 
(13)
Minimum 
(14)
Maximum 
(15)
Mean 
(16)
Mode 
(17)
Cannabis resin (1 gram)
Herbal cannabis (type unspecified) (1 gram) (11)
— sinsemilla (1 gram)
— other herbal cannabis (European/non-European seeded 
herbal cannabis) (1 gram)
Heroin (type unspecified) (1 gram) (12)
— Heroin brown (1 gram)
— Heroin white (1 gram)
Cocaine (1 gram)
Crack (1 gram)
Amphetamine (1 gram)
Methamphetamine (1 gram)
Ecstasy-type substances (1 tablet/unit) (10)
LSD (1 dose/unit)
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Standard Table 16 continued 
METHODOLOGICAL COMMENTS
1. Are there inconsistencies with data previously submitted? If there are, please identify them and state the reason(s) (e.g. update,  
previous mistake, etc.).
2. What is the type of information system (source) from which the data are provided? (e.g. routine monitoring system, repeated survey/ 
study, ad hoc survey/study).
3. What is the timeframe of data collection? (e.g. continuous/permanent, number of times per year and duration/dates, once a year  
and duration/date).
4. What is the geographical coverage of the data provided? (e.g. national, local, number and type of sites covered).
5. What is the method used to collect data on drug prices at retail/street level (e.g. surveys among users, police estimates, test purchases)? 
Please describe the methodology used to collect and/or estimate data on drug prices (sampling strategy, number of estimates collected, 
whether it refers to a particular setting, etc.). 
6. How are prices per gram determined (e.g. based on real weight (weighed amounts), estimated from non-weighed smaller amounts for 
sale)? If it is the case, please mention any conversion rule used (e.g. to convert price of crack per rock into per gram, to convert price of 
heroin per street dose into per gram).
7. Please mention any deviation from what is requested in the data submitted (e.g. weighted mean instead of arithmetic mean, median  
instead of mode, prices per other amount than the one requested).
8. Please mention potential biases (and their direction) to be taken into account when interpreting the data (e.g. biases related to coverage,  
sampling strategy, level of the drug market, etc.).
9. In countries where the national currency is NOT the euro, please provide any comment/data that may be relevant for interpretation of 
trends (e.g. stable trend in national currency but not in euros due to variations in exchange rates). You may report here your data in  
national currency (only if you wish to do so).
10. Please provide relevant bibliographic references.
11. Other comments.
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Metropolitan Police Service Covert Drug Purchases Database Form
Restricted
Covert Drug Purchase Operations: 
Drug Price and Purity Data 
Form to be completed by the Exhibits Officer
Exhibits Officer (name)
E-mail address
Telephone number
Forensic Science Service 
Reference
CRIS Reference
Custody Record Reference
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Metropolitan Police Service
Metropolitan Police Service Covert Drug Purchases Form (Form CDP 1)
Operation name Pseudonym of officer making purchase Sex Age
Ethnic 
code
Unit/borough running 
operation 
Date of 
purchase
Time of 
purchase
Location of purchase Post code
Offender’s full name 
Surname First name(s)
Sex Age Date of birth
Ethnic 
code
Place 
of birth Nationality
CRO or PNC number Officer in case (OIC) E-mail address
D
ru
g 
ty
pe
(s
)
Crack
A
m
ou
nt
(s
)
Pr
ic
es
 (G
BP
)
Po
lic
e 
Ex
hi
bi
t r
ef
er
en
ce
 a
nd
 E
xh
ib
it 
ba
g 
nu
m
be
r
W
ei
gh
t(s
): 
af
te
r F
SS
 a
na
ly
si
s
Pu
rit
y:
 a
fte
r F
SS
 a
na
ly
si
s
Cocaine 
(powder)
Heroin 
Ecstasy
LSD
Methadone
Opium
Cannabis
Cannabis 
resin
Ampheta- 
mine
Other 
(specify)
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Notice 10-06 Item 2 of the Metropolitan Police Service 
The Metropolitan Police Service’s (MPS) Covert Drug Purchases Database: 
Monitoring the price and purity of heroin, cocaine and other controlled 
drugs
(CR 216/04/17 and DP7/05/1)
Introduction
The purpose of this Notice is to set out the Specialist Crime Directorate’s (SCD) criteria and 
procedure for monitoring the price and purity of heroin (crude diamorphine), cocaine (including 
crack) and other controlled drugs. Analyses of these data will:
improve the understanding by MPS of the price and purity of specific drugs across London; ▯
support Operation Paramount — a national drug price index that is collated by the National  ▯
Criminal Intelligence Service and will be incorporated into the functions of the new Serious 
and Organised Crime Agency;
help MPS to have a greater understanding of drugs markets; ▯
help the SCD Central Drug Trafficking Database (CDTD) project team to monitor and evaluate  ▯
the effectiveness of the tactic of covert drug purchases as a means for disrupting those 
organised crime networks involved in the trafficking of specific drugs;
assist the courts in determining appropriate sentences.  ▯
The results of this research will be incorporated into the National Intelligence Model (NIM) 
strategic and tactical assessments produced by the CDTD Project team, and made available to 
MPS staff. The research findings will also be available to statutory and non-statutory agencies 
working with the MPS. 
Background
Drug price and purity information provides important intelligence. For intelligence to have true 
value it must come from a reliable source and be as accurate as possible. As prices and purities 
vary considerably, the presentation of aggregate data must use the best statistical techniques 
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available. Research has shown that information from police test purchase operations is the most 
reliable and accurate data source available. A methodology to collate and present this data has 
been developed after a pilot project in 2004. The procedure to be followed is outlined below, 
which has been agreed with the Detective Chief Inspector of SCD11(10) Covert Operations. 
Recording price and purity of specified controlled drugs: procedure
Details of all (starting from Sunday 1 January 2006) covert drug purchases will be recorded 
on the Covert Drug Purchase (CDP) form. Blank CDP forms can be found on the MPS Forms 
intranet site (form number 196). An example of a completed CPD form is at Annex 1 of this 
Notice. The responsibility for completing the CDP form will rest with the police officer deputed to 
act as the Exhibits Officer for the duration of the Test Purchase Operation (TPO) or Undercover 
Buy Operation (UBO). The form is designed to be completed on screen so that it can be sent by 
e-mail to the Drugs Directorate (SCD3-CDP) for analysis. 
One CDP form will be completed for each transaction. So, for example, in the case where 
a police officer carries out two test purchases from the same offender, at the same location in the 
course of one day, then the CDP form will be completed twice. In cases where the police officer 
buys two drugs (say crack and heroin) at the same time and from the same offender, then only 
one CDP form will be used, but the Exhibits Officer must record the details of both drugs on the 
form. When completing the CDP form, the Exhibits Officer should make every effort to ensure 
that information is entered in the fields relating to drug type(s), amount(s), price(s), police exhibit 
reference(s) and exhibit bag number(s), weight(s) and purity, and that the details recorded match 
those on the laboratory form 1 and the witness statement provided by the forensic scientist. It 
is accepted that, in many cases, the police officers involved in the TPO or UBO will not know 
the identity of the person selling the drug. In these cases, the Exhibits Officer will not be able to 
complete the fields relating to the offender (for example name, age, date of birth, place of birth, 
nationality and CRO/Police National Computer number). 
As soon as the result of the forensic analysis is known, the relevant fields on the CDP form will 
be completed. The Exhibits Officer will then send the completed CDP form to the group e-mail 
address SCD3-CDP using the MPS AWARE system.
The Senior Investigating Officer in charge of the TPO or UBO is responsible for ensuring that there 
is no undue delay in the completion of the CPD form. 
On receipt, the CPD form will be reviewed. If any errors or discrepancies are found the Exhibits 
Officer will be contacted by return e-mail. 
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The information relating to prices, purity, drug type and so on will be scrutinised, validated and 
entered onto the SCD Covert Drug Purchase Database. It will be analysed and the results will be 
incorporated into the NIM strategic and tactical assessments produced by the CDTD Project team. 
Definitions
Covert Drug Purchase
For the purpose of this Notice, the term ‘covert drug purchase’ means:
the purchase of any controlled drug ▯
the purchase of any non-controlled drug (for example ephedrine, caffeine, aspirin) ▯
the purchase of any innocuous substance (for example chalk, soap, plaster) ▯
by a Test Purchase Officer or an Undercover Officer whilst acting as such. ▯
Controlled Drug
The term ‘controlled drug’ means any drug mentioned in Schedule 2, Part I, II or III to the Misuse 
of Drugs Act 1971. 
Application
This Notice is of particular relevance to:
Undercover Officers; ▯
Test Purchase Officers; ▯
Officers designated as Exhibits Officer in operations involving the covert purchasing of  ▯
controlled drugs;
Senior Officers planning, supervising and managing operations involving the covert purchases  ▯
of controlled drugs;
Criminal Justice Unit Managers and their deputies; ▯
Staff in the Drugs Directorate;  ▯
Staff in the SCD11 (Covert Policing Unit).  ▯
For more information regarding this Notice please contact [the Drugs Directorate Drug Prevention] 
Inspector on extension xxxx or by e-mail.
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Statistics and indicators: examples of calculation 
This annex presents simple equations for some of the statistics discussed in the text and are 
targeted at those readers with little or no previous statistical experience. These few notes are not a 
substitute for a good statistical reference, such as that by Kirkwood and Sterne (2003) referenced 
in the bibliography, which will prove invaluable when working with data.
Any statistical computing package will have routines to generate these descriptive statistics. 
Equally, all spreadsheet packages will have functions to generate these statistics. Note that it is 
important to understand how any computer package used calculates statistics as not all are the 
same. 
Notation
Let:
n = sample size.
X = the variable price of cocaine per gram in euros.
xi = a specific realisation of the variable X.
The subscript i is used to denote a specific observation of a variable, sample, or weight.
For example:
xi = is the ith specific observation on the price of cocaine per gram.
i = 1 .. n
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
X = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
195
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
 = the summation operator. Sum the observations on X between 1 and n.
Arithmetic mean 
The arithmetic mean is obtained by summing the values in the data set and dividing by the count.
Symbolically
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
X = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
195
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
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Example 1 
A sample of 10 prices per gram of cocaine were recorded 30, 35, 40, 40, 50, 50, 60, 60, 65, 70
n = 10
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
X = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
195
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
The sample mean price of cocaine per gram in euros = 50.
Example 2 
The arithmetic mean is sensitive to extreme values, commonly referred to as outliers.
Consider the effect on the mean of changing a single value in the sample to an extreme value. 
x10 is changed from 70 to 250.
A sample of 10 prices per gram of cocaine were recorded 30, 35, 40, 40, 50, 50, 60, 60, 65, 250
n = 10
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
 = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
95
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
The sample mean price of cocaine per gram in euros = 68. 
Here the arithmetic mean is not a particularly good representative value of the sample, being 
greater than 9 observations, and less than only 1.
Weighted mean 
A weighted mean is appropriate where the values being summed do not have equal importance. 
The weighted mean is calculated by multiplying each value in the sample by its associated weight 
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and dividing by the sum of the weights. Equivalently, scale the weights so their sum equals 1, then 
multiply each value in the sample by the scaled weight and sum.
Symbolically:
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
X = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
195
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
where wi ≥ 0
Example 3 
Consider the following two samples:
Sample 1.
30, 35, 40, 40, 50, 50, 60
n1 = 7
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
X = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
195
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
Sample 2.
60, 65, 70
n2 = 3
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
X = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
195
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
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Combining sample 1 and sample 2 and calculating the mean.
n = 10
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
X = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
195
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
The combined sample mean price of cocaine per gram in euros = 50.
Consider a situation where the raw data are not available, and only the two sample means and 
their sample size are reported, 
Sample 1: mean price of cocaine per gram is 43.571 calculated from 7 observations.
Sample 2: mean price of cocaine per gram is 65 calculated from 3 observations.
To combine the two means into an overall mean it is necessary to consider the relative importance 
of the two statistics. Sample 1 is greater in size than sample 2 and should receive more relative 
importance in the calculation of a combined value.
Calculating an arithmetic mean of the two average prices would ignore the difference in relative 
importance.
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
X = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
195
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
  
WRONG.
A weighted mean is needed. The weights are equal to the size of the sample.
w1 = 7
w2 = 3
w1 + w2 = 10
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
X = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
195
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
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Equivalently, scaling the weights so their sum equals 1.
w1 = 7/10
w2 = 3/10
w1 + w2 = 1
xi = x1 + x2 + ... + xn
n
i=1
�
xi
n
i=1
�
nX =
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 250 = 680
X = = 6868010
X = = 5050010
X1 = = 43.571
305
7
X = = 5050010
wi xi
n
i=1
�
wi
n
i=1
�
X =
 
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 = 305
xi
n
i=1
� = 30 + 35 + 40 + 40 + 50 + 50 + 60 + 60 + 65 + 70 = 500
X2 = = 65
195
3
xi
n2
i=1
� = 60 + 65 + 70 = 195
 
= 54.28643.571 + 652
!
= 50= 7 * 43.571 + 3 * 657 + 3
wi xi
n
i=1
�
wi
n
i=1
�
X =
* 43.571 +      * 65 = 50
7
10
3
10
Median 
The median refers to the value that divides the sample into two equal numbers of observations, 
e.g. for a list of drug prices, an equal number of observations will fall below and above the 
median.
The median is obtained by ordering the observations from the smallest to the largest and taking 
the middle value. For an odd number of observations the median is a specific value. Having 
ordered the observations from small to large the median is the (n +1)/2 observation. 
For an even number of observations take the arithmetic mean of the two central values to obtain 
the median. Equivalently, having ordered the data from small to large, take the arithmetic mean of 
the n/2 value and the (n/2 + 1) value.
Example 4 (odd number of observations) 
A sample of 11 prices per gram of cocaine were recorded:
30, 35, 40, 40, 50, 50, 60, 60, 65, 70, 80
n = 11
(11 + 1) /2 = 6.
The 6th observation is 50.
30, 35, 40, 40, 50,  50, 60, 60, 65, 70, 80
The median value is EUR 50 per gram.
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Example 5 (even number of observations) 
A sample of 10 prices per gram of cocaine were recorded:
35, 40, 40, 50, 50, 60, 60, 65, 70, 80
n = 10
n/2 = 5
n/2 + 1 = 6
The 5th and 6th observations are 50 and 60 respectively in this case.
35, 40, 40, 50, 50, 60, 60, 65, 70, 80
50 + 60  = 552
The median value is EUR 50 per gram.
Mode  
The mode is the most frequently occurring value in the data set. Where there is a tie for the most 
frequently occurring value, the dataset will have more than one mode. 
Example 6
A sample of 10 prices per gram of cocaine were recorded:
30, 35, 40, 40, 50, 55, 60, 65, 70, 75
The most frequently occurring value is 40, occurring twice while all other values occur only once.
30, 35, 40, 40, 50, 55, 60, 65, 70, 75
The modal value is 40.
Example 7
Some datasets will express more than one mode. 
A sample of 10 prices per gram of cocaine were recorded:
30, 35, 40, 40, 50, 55, 60, 60, 65, 70
Here the values 40 and 60 both occur twice, resulting in more than one modal value.
30, 35, 40, 40, 50, 55, 60, 60, 65, 70
A distribution with two modes is said to be ‘bi-modal’. With large datasets bi-modal and multi-
modal distributions can sometimes be an indication that a factor should be sought that would 
break the data into more distributions, each modal value being the centre of a distribution. 
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Minimum  
The minimum is the smallest value. 
Example 8
A sample of 10 prices per gram of cocaine were recorded:
30, 30, 40, 40, 50, 55, 60, 60, 65, 70
The minimum value is 30.
Maximum  
The maximum is the largest value.
Example 9
A sample of 10 prices per gram of cocaine were recorded:
30, 30, 40, 40, 50, 55, 60, 60, 65, 70
The maximum value is 70.
Range   
A sample of 10 prices per gram of cocaine were recorded:
Example 10
A sample of 10 prices per gram of cocaine were recorded:
30, 35, 40, 40, 50, 50, 60, 60, 65, 70
The range is 70 – 30 = 40.
Quartiles   
Having ordered the data from the smallest to largest value, the quartiles split the data into four 
equally sized groups, size being in terms of number of observations. 
The first or lower quartile is the observation that leaves roughly 25 % of the data points below it 
and 75 % above it.
The second quartile is the median, the data point that splits the ranking into two equally sized 
groups, 50 % of the distribution appearing below the data point and 50 % above.
The third or upper quartile is the data point that leaves roughly 75 % of the data points below it 
and 25 % above it.
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There are a number of different methods of calculating quartiles. A simple method is to calculate 
the median value, split the data set around the median, then calculate the medians for the upper 
and lower half of the data. For an even number of observations the data set splits easily into two 
equal halves. For an odd number of observations, include the median value in both the upper and 
lower halves.
Example 11 (odd number of observations)
A sample of 11 prices per gram of cocaine were recorded:
30, 35, 40, 45, 50, 50, 60, 60, 65, 70, 80
n = 11
(11 + 1) /2 = 6.
The 6th observation is 50.
30, 35, 40, 45, 45, 50, 60, 60, 65, 70, 80
The median value is EUR 50 per gram
Breaking the sample into two parts.
The lower part:
30, 35, 40, 45, 45, 50
Finding the median of the lower part by taking the arithmetic mean of the two central values.
40 + 45  = 42.52
The first or lower quartile equal 42.5.
The upper part:
50, 60, 60, 65, 70, 80
Finding the median of the upper part by taking the arithmetic mean of the two central values.
60 + 65  = 62.52
For the sample, the lower quartile is 42.5, the median is 50 and the upper quartile is 62.5.
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Example 12 (even number of observations)
A sample of 10 prices per gram of cocaine were recorded:
35, 45, 40, 50, 50, 60, 60, 65, 70, 80
n = 10
n/2 = 10
n/2 + 1 = 10
The 5th and 6th observations are 50 and 60 respectively in this case.
35, 40, 40, 50, 50, 60, 60, 65, 70, 80
The median value is EUR 50 per gram
Breaking the sample into two parts.
50 + 60  = 552
The median value is EUR 55 per gram.
Breaking the sample into two parts.
The lower part:
35, 40, 40, 50, 50
Finding the median value of the lower part.
n = 5
(5 + 1)/2 = 3
The third value is 40.
35, 40, 40, 50, 50
The upper part:
60, 60, 65, 70, 80
Finding the median value of the lower part.
n = 5
(5 + 1)/2 = 3
The third value is 65.
60, 60, 65, 70, 80
For the sample, the lower quartile is 40, the median is 55 and the upper quartile is 65.
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